

International Pharmaceutical Manufacturers Group

Improving Access to Innovation, Inspiring Health

IPMG Annual Report 2024

Accessible innovative medicines and vaccines are fundamental to IPMG's mission. We recognize that innovative medicines can only deliver their full value and impact when they reach those who need them. In pursuit of impactful collaboration, IPMG actively seeks engagement with the government and key stakeholders in the health sector to promote policies that accelerate the availability and accessibility of life-saving innovations. By fostering an environment that prioritizes patient-centered solutions, we strive to ensure that advancements in medicine translate into tangible health benefits for all.



Chairwoman's Letter	(
Tribute to IPMG Outgoing Chairman	8

10

34

IP	MG MANIFESTO	10
•	Preamble	11
•	Why It Matters?	12
•	Why Now?	17
•	Our Support	18
•	IPMG Contributions	20
•	The Asks of IPMG Manifesto	22
•	Focus Areas in 2025	28

CHAPTER 01

About IPMG

a. IPMG at a Glance

- b. Vision, Mission, and Goals
- 2024 Board Composition
 - Board of Management
 - Board of Supervisors
- d. 2024-2026 Board Composition
 - Board of Management
 - Board of Supervisors
- e. IPMG Membership

IPMG ANNUAL REPORT 2024

CHAPTER 02

IPMG's Task Forces 44

a.	Communications Task Force	45
b.	Industrial Policy	47
с.	Market Access (JKN Drug Enlistment)	49
d.	Market Access (Affordability)	50
e.	Partnering for Health Advancement	53
f.	Ethics, Medical, and Patient Safety	54
g.	Regulatory Affairs	55

CHAPTER 03

IPMG's Vision and Focus in 2025

- a. IPMG Members' Profile
- b. Members' Contribution to Indonesia

86

c. Members' Awards and Recognitions 126

Chairwoman's Letter

Dear Members, Partners, and Stakeholders,

As we reflect on the past year, I am proud to present this Annual Report, which captures the progress, challenges, and milestones that have shaped our journey at IPMG. In an everevolving healthcare landscape, our commitment to advancing patient access to innovative, highquality medicines has remained unwavering. The past year has been marked by meaningful collaboration, strong advocacy, and tangible impact. We have deepened our engagement with policymakers and industry leaders to foster a regulatory environment that encourages innovation while upholding the highest standards of patient safety. Our resolve to expand access to every citizen has remained firm, driven by our collective belief that healthcare is a fundamental right.

Through the unified efforts of IPMG, we have continued to promote ethical standards, encourage investment in healthcare, and contribute to Indonesia's vision for a sustainable and resilient pharmaceutical ecosystem. Our members' dedication to scientific advancement, patient-centric solutions, and industry integrity has driven transformative change. From supporting national public health initiatives to adapting to dynamic policies, IPMG remains a vital force in shaping a healthcare system that serves all. Looking ahead, we recognize both the opportunities and the challenges that lie before us. Strengthening partnerships, embracing innovation, and advocating for inclusive and forward-thinking policies will remain our key priorities. With continued collaboration and purpose, I am confident that we will deliver even greater impact in the years to come.

I would also like to take this opportunity to express my heartfelt gratitude to our members, partners, and stakeholders for your steadfast support and shared commitment. Together, we will continue building a healthier, more equitable future for all Indonesians.

Finally, I wish to acknowledge and honor Dr. Ait-Allah Mejri, our outgoing Chairman, whose bold vision and unwavering dedication to public health have left a lasting legacy. Under his leadership, IPMG introduced its landmark manifesto—a bold and practical roadmap for a national strategy on new medicines and vaccines. This manifesto offers actionable solutions that not only expand equitable access and encourage innovation but also align with both national and global health priorities while responsibly managing healthcare costs. Dr. Mejri has been an integral part of IPMG's journey, and we are deeply grateful for his leadership and vision.

With optimism and resolve, we move forward—together.

7



Tribute to IPMG Outgoing Chairman

Dr. Ait-Allah Mejri Concludes His Tenure as Chairman in March 2025

The International Pharmaceutical Manufacturers Group (IPMG) enters an exciting new phase as Dr. Ait-Allah Mejri concludes his tenure following five years of exceptional leadership. A former public health physician and long-serving President Director of PT Roche Indonesia, Dr. Mejri has served as Chair of IPMG since February 2019.

During his leadership, IPMG has been a steadfast champion of sustainable innovation and has actively fostered collaborations aimed at improving healthcare outcomes across Indonesia. Under Dr. Mejri's guidance, IPMG achieved notable advancements in healthcare innovation, patient advocacy, and stronger industry partnerships.

Reflecting on his time as Chairman, Dr. Mejri shared:

"It has been a tremendous honor to lead IPMG alongside such dedicated board members during a period of transformation in Indonesia's healthcare landscape. Over the past five years, we've strengthened our partnerships and solidified our role as a trusted collaborator in advancing access and innovation in healthcare." The IPMG Secretariat, Board Members, General Members, and Task Force Members unanimously extend their heartfelt gratitude to Dr. Ait-Allah Mejri for his visionary leadership, unwavering dedication, and impactful contributions to public health in Indonesia. We wish him and his family continued joy, good health, and all the best in the journey ahead.



9



IPMG Manifesto

Last year, IPMG proudly launched the IPMG Manifesto—a strategic roadmap designed to transform access to medical innovation in Indonesia. The manifesto outlines a clear vision for progress, calling for effective and sustained partnerships between government and healthcare stakeholders. It offers practical, actionable solutions to expand equitable access to medicines, foster innovation, and align healthcare policies with national priorities.

By adopting these solutions, Indonesia stands to gain significant benefits: better health outcomes, stronger economic resilience, and a meaningful reduction in outbound medical tourism. At its core, the manifesto is a call to collective action inviting all stakeholders to work together to turn these solutions into impactful strategies that improve lives across the nation.

The launch of the manifesto was marked by a significant moment of unity at the IPMG Stakeholder Forum in December 2024, Jakarta, attended by key representatives from the government, patient advocacy groups, medical associations, academia, and industry. The forum embodied a spirit of openness and shared purpose—anchored in the common goal of strengthening Indonesia's healthcare system to serve millions more, and serve them better. We deeply value Minister Budi's recognition of the manifesto's objectives and his public commitment to advancing its five strategic priorities. His support reflects a shared confidence in the power of collaboration to create a sustainable and inclusive pathway to greater access, more robust universal health coverage, and improved healthcare outcomes for all Indonesians.

Looking ahead, IPMG remains deeply committed to close collaboration with all healthcare partners. We are prepared to co-develop fair and sustainable pricing solutions that support both public and private healthcare systems—while keeping patients at the heart of every decision. In addition, we offer our expertise, data, and resources to help translate the manifesto's vision into concrete, impactful actions that drive real change.

Together, we have a unique opportunity to shape the future of healthcare in Indonesia. IPMG looks forward to continuing this meaningful partnership—and translating our shared aspirations into real, measurable change for the nation's health.



Preamble

Indonesia's introduction of a national health insurance scheme (JKN) in 2014 marks a significant milestone in public health policy. Successfully expanding health coverage to over 280 million people is not only a remarkable achievement but also a testament to the country's commitment to improving the wellbeing of its citizens. IPMG applauds and supports this ambitious endeavor that sets a strong foundation for continued progress in healthcare access and equity. IPMG remains concerned that the current healthcare system in Indonesia does not prioritize access to innovative medicines.

A fragmented legislative environment and the lack of strategic coordination is hindering the availability of new treatments, negatively affecting the quality of care and undermining the trust of Indonesians in their healthcare system. The policy vacuum around new medicines is reflected in the numbers (see next slide). This has to change. Indonesia is a contestant in a regional competition for a better health service. However, its ability to compete is being hampered and held back. Despite a solid economic performance in the last decade, transforming economic growth into better health outcomes has lagged behind neighboring countries. This manifesto lays out workable and practical suggestions for a comprehensive national strategy for new medicines and vaccines that will contribute to equitable access, promote innovation, manage costs, and aligns healthcare policies with national and global health priorities.

These measures can support the sustainability of and restore trust in the national healthcare system. The potential benefits are immense, with trillions of rupiah of savings at stake from improved outcomes as well as the opportunity to reduce the number of Indonesians travelling abroad for medical treatment.

We urge the next government to recognize the critical importance of having a national strategy for new medicines coming to the market and engage in a true partnership with the industry centered on the principles of collaboration, transparency of delivery, and a unified approach to health and growth.

Why It Matters?

The absence of a **National Guideline for Innovative Medicines and Vaccines** significantly hampers patient access to life-saving treatments.

85%

Currently, Indonesia lacks an established framework for the adoption of new medicines, placing it far behind its regional and G20 counterparts.

Indonesia **Has Fewer New Medicines** Available Than Any Other G20 Countries


Only 9% of new medicines are available in Indonesia Indonesia has fewer new medicines available than any other G20 country

Percentage of new medicines available by G20 Countries (of all 460 new medicines launched from 2012 to the end of 2021)




According to the PhRMA Report 2023, there are 460 new medicines launched globally between 2012 to the end of 2021¹. However only **9% out of 460 new medicines** are available in Indonesia,

and the situation is even more critical for BPJS Kesehatan beneficiaries, where access is limited to a mere **2% of new medicines²**.




This gap in availability underscores the need for an urgent policy shift to ensure that Indonesian patients benefit from medical advancements at the same pace as other nations.

 ¹ Pharmaceutical Research and Manufacturer of America (PhRMA), Global Access to New Medicines Report, 2023, p. 11.
 ² Ibid., p. 17.



Beyond patient care, the economic burden of disease is staggering. Indonesia loses approximately **\$201 billion in economic output annually** due to productivity loss from both non-communicable and communicable diseases, equivalent to about **19% of GDP**³.

Of this, **\$101 billion** is attributed to communicable diseases alone. However, through better prevention and treatment strategies, **\$130 billion—around 14% of GDP—could be saved**, highlighting the significant financial and economic advantages of investing in healthcare reform and innovation⁴.



³ Lim et al., Indonesia 2030: The \$68 Billion Healthcare Opportunity, 2019.

⁴ Ibid

IPMG ANNUAL REPORT 2024





Why Now

Moreover, Innovation driven R&D brings new treatments to patients that can transform health outcomes and their quality of life. Timely and equitable access to standard of care services and interventions is a key component of UHC.

Indonesia is presented with a unique opportunity to shift from funding "sickness systems" to investing in health – enabling earlier action to prevent, diagnose and treat disease². The WHO supports the inclusion of fundamental, life-saving products into lists of essential medicines for countries that do not have readily available standards of care – aiming to keeping standards up to date with new innovations.

Investing in health is not just a moral imperative but a strategic economic decision.

- Every \$1 invested in health yields a potential return of \$2–4, making healthcare an essential driver of economic growth⁵.
- Furthermore, embedding quality within Indonesia's healthcare system represents an economic opportunity worth \$68 billion, strengthening
 local research, innovation capacity,

and job creation. Recognizing these factors, IPMG sees a unique and urgent opportunity to improve health outcomes, stimulate local research and innovation, and promote economic growth.

Since 2014 and the launch of JKN, remarkable progress has been made:

- Expanding of coverage to 96% of 280 million citizens.
- Securing universal coverage for high priority services such as for maternal and child-health.
- Putting a focus on the inexorable rise of NCDs.

The ambitious health transformation plan spanned across 2021-2024 aims to improve the quality of care so the system is responsive to and meets the needs of patients.

⁵ Remes et al., Prioritizing Health: A Prescription for Prosperity, 2020.

Our Support

The innovative pharmaceutical industry has the potential to drive the health and wealth of Indonesia by:

- Improving healthcare outcomes
- Strengthening research and innovation capacity
- Promoting economic growth and job creation

Improved Healthcare Outcomes

Access to Innovative Treatments:

IPMG brings life-saving therapies and vaccines that address unmet medical needs, improving patient survival and quality of life.

Disease Control and Prevention:

IPMG Advances help reduce the burden of infectious and chronic diseases, leading to a healthier population.

Healthcare System Strengthening:

IPMG collaboration with government and healthcare providers fosters better diagnosis, treatment protocols, and infrastructure development.



Local Research and Innovation Capacity

Collaborative R&D Programs:

Partnerships between pharmaceutical companies, universities, and local researchers encourage knowledge exchange and scientific progress.

Clinical Trials and Real-World Data

(RWD): Clinical trials conducted locally provide access to new treatments, boost research infrastructure, and generate evidence tailored to the region's needs.

Technology Transfer: IPMG can help transfer advanced technologies to local institutions, fostering long-term innovation capacity.



Economic Growth and Job Creation

High-Quality Employment:


IPMG creates well-paying jobs for skilled professionals, including scientists, pharmacists, and healthcare workers.

With the right policies—such as fostering innovation, building partnerships, and ensuring universal access— Indonesia can leverage the industry's expertise for sustainable growth and better health outcomes.

IPMG Contributions

IPMG continued to improve its contribution to strengthening the healthcare system and public health.






Export Destinations



The Asks of IPMG Manifesto

IPMG has identified five key policy priorities to enhance Indonesia's healthcare and pharmaceutical ecosystem, urging the government to take decisive action in critical areas that impact patient access, market competitiveness, and the sustainability of the healthcare financing system.



IPMG Manifesto



ask 01

Mobilize a dedicated task force to develop and implement a National Strategy for Innovative Medicines and Vaccines

Ensuring Indonesia becomes more regionally competitive. Currently, the fragmented legislative environment and lack of coordination among multiple institutions hinder the timely availability of new medicines. Without a central authority overseeing policy direction, efforts to streamline processes and improve market competitiveness remain disjointed. Establishing a dedicated office would enable strategic coordination, improve standards of care, and position Indonesia as a leader in medical services within the region.



ask 02

Review of the current "Negotiation and Pricing Model" and "Procurement and Tendering System" in BPJS


Emphasizing the need for fair and transparent pricing mechanisms. IPMG argues that arbitrary government-imposed price controls on life-saving medicines are not aligned with good public policy and could lead to unintended consequences such as shortages or reduced availability of high-quality medicines. Instead, they advocate for valuebased pricing negotiations between manufacturers and BPJS, ensuring affordability without compromising quality. Additionally, procurement processes should be made more predictable and efficient, mitigating risks of supply chain disruptions and ensuring patients have consistent access to essential medicines.



ask 03

Enable industry involvement in Health Technology Assessment (HTA)

While strengthening national HTA institutions. A major concern is the significant backlog of over 140 products awaiting HTA assessments, which delays patient access to innovative treatments and places Indonesia among the lowest in the G20 and ASEAN regions in terms of new medicine adoption. While respecting the independence of HTA institutions, IPMG stresses the need for industry collaboration and capacity-building measures, such as resource enhancement, training, and a robust multi-stakeholder framework for assessment and listing decisions. This approach would lead to more efficient and ethical HTA processes, ensuring Indonesian patients benefit from the latest medical advancements without undermining regulatory integrity.



азк **04**

Strengthen the regulatory framework under BPOM

Particularly by streamlining approval pathways for critical medicines. Current regulatory approval processes are often slow and cumbersome, creating barriers to timely access for treatments addressing rare diseases, life-threatening conditions, and public health emergencies such as pandemics. To address these inefficiencies, IPMG urges the government to adopt accelerated approval pathways and align BPOM's regulatory processes with international standards set by organizations such as the International Council for Harmonisation (ICH) and the World Health Organization (WHO). This alignment would help reduce delays, enabling faster market access to innovative treatments while maintaining high safety and efficacy standards.



азк **05**

Invest in health for a resilient future

Recognizing that healthcare expenditure should be seen as a longterm investment rather than a cost burden. With Indonesia's aging population and the growing prevalence of chronic diseases, a strategic approach to health spending is needed. The COVID-19 pandemic further underscored the importance of a well-funded and efficient healthcare system. IPMG advocates for increased health budgets, infrastructure upgrades, digitalization, and better prevention programs to enhance overall system resilience. Additionally, targeted efforts to reduce medical waste—including addressing clinical inefficiencies, fraud, and missed prevention opportunities—must be prioritized to optimize spending and maximize health outcomes.

By addressing these five key areas, IPMG envisions a stronger, more competitive, and patient-centered healthcare system in Indonesia, ensuring that innovative treatments are accessible, regulatory processes are streamlined, and health investments are optimized for long-term national development.

Focus Areas in 2025

To realize this potential, IPMG task forces are committed to advocate the IPMG Manifesto, urging the government to acknowledge the critical need for a national strategy on new medicines. A true partnership between the government and key stakeholders—based on collaboration, transparency, and a unified approach to health and economic development is essential to achieving these goals. For this reason IPMG will focus its efforts within the five strategic pillars of the manifesto.



Mobilize a dedicated task force to develop and implement a National Strategy for Innovative Medicines and Vaccines.

Focus:

Establish a partnership to mobilize a task force and develop a strategic framework by working together with government and key stakeholders to shape a highlevel, cross-sectoral task force that can support the development and implementation of a national strategy for innovative medicines and vaccines.

Proposed Collaborative Steps:

- Joint Stakeholder Mapping & Engagement: Support efforts to identify representatives from ministries (Health, Finance, Planning, Industry), BPOM, private sector, and academia.
- Support task force formation: Contribute to the establishment of the task force by offering technical input and collaborative frameworks.
- Establish a coordination mechanism: Assist in setting up a communication and progress-tracking hub aligned with national health priorities.



Review of the current "Negotiation and Pricing Model" and "Procurement and Tendering System" in BPJS.

Focus:

Contribute expertise to ongoing efforts to enhance fairness, efficiency, and accessibility in medicine pricing and procurement systems.

Proposed Collaborative Steps:

- Participate in Action Groups: Engage in joint working groups alongside stakeholders from key ministries and institutions.
- Share Global Insights: Offer comparative benchmarking based on international best practices in procurement and pricing models.
 - Work Toward Sustainable Solutions: Co-develop reform suggestions that are viable in both the short and long term.



3. Enable industry involvement in Health Technology Assessment (HTA

Focus:

Collaborate on strengthening the national HTA system to ensure that health decisions are grounded in robust evidence and aligned with evolving needs.

Proposed Collaborative Steps:

- Public-Private Dialogue: Facilitate closer engagement between HTA bodies and the industry by creating advisory groups or joining working sessions to ensure scientific and economic perspectives are integrated.
- Engage Global Perspectives: Leverage international best practices and invite international experts (e.g., NICE, WHO) to share insights on HTA capacity building.
- Capacity Development: Co-create training programs to enhance the ability of HTA institutions to conduct evidencebased assessments.



Strengthen the regulatory framework under BPOM Focus: Propose

Contribute to ongoing efforts to modernize and align Indonesia's regulatory systems with global best practices.

Proposed Collaborative Steps:

- Regulatory Capacity Building: Facilitate expert-led workshops and knowledge exchange programs with international agencies.
- Enhance Transparency & Efficiency: Support the development of e-regulation systems for drug and vaccine approvals, improving timelines and process visibility.




5. Invest in health for a resilient future Focus:

Collaborate in building a strong case for increased health investments that deliver broad benefits — from improved population health to greater economic productivity.

Proposed Collaborative Steps:

- Policy Dialogue & Evidence Sharing: Highlight the broader socioeconomic benefits of investment in health (e.g., reduced medical tourism, higher workforce productivity).
- Support Resource Allocation Strategies: Offer tools and insights to help ensure efficient allocation of health budgets to strategic priority areas.



CHAPTER 01

About IPMG

a.	IPMG at a Glance	32
b.	Vision, Mission, and Goals	34
с.	2024 Board Composition	36
	Board of Management	
	Board of Supervisors	
d.	2024-2026 Board Composition	38
	Board of Management	
	Board of Supervisors	
e.	IPMG Membership	40

IPMG at a Glance

IPMG represents innovative researchbased biopharmaceutical companies, small, medium, and large, operating in Indonesia. IPMG seeks to play an important role as a Partner to the HealthCare Stakeholders in improving Indonesia's healthcare system. IPMG communicates the role and contribution of R&D-based pharmaceutical manufacturers in helping people improve their quality of life as well as pushing for an advancement of an effective and integrated healthcare system in Indonesia.

- To represent the opinions and interests of IPMG members in discussions with the government, regulatory agencies, trade associations, professional associations, and local national pharmaceutical business.
- To promote and safeguard members' interests in Indonesia by striving to influence policy developments affecting the health sector.
- 3. To analyze and interpret the trends and the impacts of changes in legislation relating to the industry
- To keep abreast of global developments in pharmaceutical policies through IPMG's international representation as a member of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA).



Vision, Mission, and Goals

In a rapidly evolving world, the importance of a strong, resilient healthcare system has never been more apparent. At the center of this effort in Indonesia stands the International Pharmaceutical Manufacturers Group (IPMG), driven by a bold and unwavering vision: to be a trusted partner to the Government of Indonesia and key stakeholders across the healthcare spectrum. IPMG strives to contribute meaningfully to the advancement of Indonesia's healthcare system by harnessing the core strengths of its members—breakthrough medical innovation and the production of pharmaceutical products that meet the highest international standards of quality and safety. This vision is grounded in a deep commitment.

IPMG believes in the power of true partnership. It works closely with the government and health stakeholders to support policies that not only stimulate economic growth but also foster innovation ultimately improving the lives of Indonesian patients. This partnership is built on trust, and IPMG honors that trust by upholding the strictest ethical standards and ensuring full compliance with both domestic and international laws and regulations. Every action taken by IPMG and its members is rooted in responsibility—to patients, to public health, and to the future of healthcare in Indonesia.

At the heart of IPMG's mission is a clear purpose: to help deliver the best possible health outcomes for the Indonesian people. This means supporting the long-term sustainability of the National Health Insurance system (JKN), aligning with national priorities to strengthen the local pharmaceutical industry, and ensuring that every citizen has access to safe, effective, and innovative treatments.

To realize this mission, IPMG focuses on three critical goals. First, ensuring that innovative medicines are accessible to those who need them. Second, co-creating a forward-thinking life-sciences ecosystem that nurtures research, development, and investment. And third, fostering robust partnerships across the healthcare system—uniting public and private sectors toward a common goal of better health for all. Behind these goals lies a deep, enduring commitment. For decades, pharmaceutical companies—many of them IPMG members have pushed the boundaries of science to develop life-changing therapies, reduce suffering, and combat both known and emerging diseases. This commitment to research and development is not just a business imperative—it is a moral one. IPMG and its members embrace this responsibility with passion and integrity.

As part of that integrity, IPMG works to create a fair, transparent, and ethical business environment. By supporting a level playing field, complying with all existing laws and regulations, and adhering strictly to the IPMG Code of Ethics, the organization ensures that the Indonesian pharmaceutical industry grows in a way that is both sustainable and aligned with the highest global standards.

Together, with innovation, collaboration, and dedication, IPMG is helping to shape a healthier future for Indonesia.



Board of Management



Dr. Ait-Allah Mejri

- Chairman
- Sponsor of Partnering for Health Advancement Task Force



Evie Yulin

- Vice Chairwoman
- Sponsor of Market Access Task Force



Andreas Gutknecht

Honorary Treasurer





Selly Kartika

- Honorary Secretary
- Sponsor of Regulatory Affairs Task Force

George Stylianou

• Sponsor of Communications Task Force



M. Idham Hamzah

• Sponsor of Industrial Policy Task Force



Sreerekha Sreenivasan

• Sponsor of Ethics, Medical and Patient Safety Task Force



Dewi Koesoema

• Co-Sponsor of Ethics, Medical and Patient Safety Task Force



Manishkumar Munot

• Board of Supervisors



Argho Das

• Board of Supervisors



Board of Management



Evie Yulin

• Chairwoman



George Stylianou

MERCK SHARP & DOHME INDONESIA

- Vice Chairman
- Sponsor of Communications Working Group

Andreas Gutknecht

TAKEDA INNOVATIVE MEDICINES

Honorary Treasurer





Selly Kartika

ABBOTT INDONESIA

Honorary Secretary

M. Idham Hamzah

MENARINI INDONESIA

• Sponsor of Health Investment Working Group





Sreerekha Sreenivasan

NOVO NORDISK INDONESIA

• Sponsor of Ethics, Medical, and Patient Safety Working Group

Dewi Koesoema

ASTELLAS PHARMA INDONESIA


• Sponsor of Health Technology Assessment Working Group

Manishkumar Munot

GLAXO WELLCOME INDONESIA /GSK

 Sponsor of Strengthening Regulatory Framework Working Group





BOEHRINGER INGELHEIM

- Board of Supervisors
- Sponsor of Pricing and Procurement Working Group

Libby Hsu

NOVARTIS INDONESIA

• Board of Supervisors





Esra Erkomay

ASTRAZENECA INDONESIA

• Board of Supervisors

Board of Supervisors





United States of America

- Abbott
- Actavis
- Johnson & Johnson
- Merck Sharp & Dohme
- Pfizer
- Organon

United Kingdom

AstraZeneca

• GSK

Germany

- Bayer
- B. Braun
- Boehringer Ingelheim
- Merck

Switzerland

- Novartis
- Roche


Denmark

Novo Nordisk

France

• Servier





CHAPTER 02

IPMG's Task Forces 44

a.	Communications Task Force	45
b.	Industrial Policy	47
с.	Market Access (JKN Drug Enlistment)	49
d.	Market Access (Affordability)	50
e.	Partnering for Health Advancement	53
f.	Ethics, Medical, and Patient Safety	54
g.	Regulatory Affairs	55

IPMG's Task Forces





Role and Responsibility

The Communications Taskforce 2024 Working Program focuses on three key areas: improving the standard of care, raising urgency for public health, and promoting recognition of innovative medicines.

The taskforce supports the IPMG Manifesto by facilitating engagement with stakeholders and advocacy for Indonesia's National Strategy for Innovative Medicines and Vaccines. Its mission is to foster collaboration, maintain momentum, and ensure clear communication among stakeholders.

To achieve this, the taskforce developed and implemented a communication strategy that highlighted key initiatives, strengthened stakeholder engagement, and promoted the value of innovative medicines and vaccines. Activities included a monthly internal newsletter, LinkedIn posts, media events, stakeholder forum, and an annual report.

Looking ahead, the taskforce strives to build a well-informed and engaged network, helping to align stakeholders with the need for a national strategy for innovative medicines and vaccines. By bridging communication gaps, it hopes to contribute to better health outcomes and a more innovative healthcare landscape in Indonesia.

This strategy aims to drive awareness, policy discussions, and healthcare improvements in Indonesia.

Key Activities

- Published IPMG Annual Report
- Promoted IPMG's values through multi communication channel
- Facilitated IPMG Stakeholder's Forum: National Strategy for Innovative Medicines and Vaccines

Sponsor

George Stylianou (PT Merck Sharp & Dohme Indonesia)

Lead

Reswita Dery Gisriani (PT Glaxo Wellcome Indonesia – GSK)

Co-Lead

Sri Libri (PT Bayer Indonesia)

Members

- Nabila Astari (PT Merck Sharp & Dohme Indonesia)
 Wanda Harahap
- (PT Abbott Indonesia) 3. Arinda Wahyuningtyas
- (PT Takeda Innovative Medicines) 4. Hestia Amriyani
 - (PT Novo Nordisk Indonesia)





02 Annual Report







03

Jakarta Post's Exclusive Interview with **IPMG Vice** Chairwoman

04

IPMG Manifesto Media Launch



The lot lot

HEADLINES

Improving people's access to new, innovative medicines

<text><text><text><text>





05

IPMG Stakeholder's Discussion Forum



Role and Responsibility

The **Industrial Policy Task Force** is dedicated to anticipating, advising, and responding promptly to changes in the policy environment impacting the pharmaceutical industry in Indonesia. Its mission is to shape government policies that enhance market attractiveness, minimize barriers to accessing innovative medicines, and drive long-term sustainable growth for the industry. The Task Force also monitored the transfer of Government and changes of policy direction post the country's presidential election.

The task force conducted proactive monitoring and assessment of emerging industrial policies, evaluating their risks, implications, and opportunities. It collaborated with relevant stakeholders to address key policy issues, including localization requirements (Tingkat Komponen Dalam Negeri/TKDN), halal certification regulations, intellectual property (IP) and patent law revisions, and compliance with Decree 1010.

Additionally, the task force led and coordinated advocacy efforts, engaging with government bodies to foster trade, regulatory, and IP policies that promote innovation and encourage multinational corporations to expand their presence in Indonesia. The task force aimed to position itself as a key enabling partner for the growth of Indonesia's biopharmaceutical sector, working towards a future state where pro-innovation policies drive longterm sustainable industry growth and investment.

Milestone and Key Activities

- TKDN re-calculation:
 - Made proposal and submitted to the Ministry of Industry
- RPMK:
 - Monitored and submitted a collaborative/joint input submission with AmCham and EuroCham
- Halal:
 - ♦ No significance
- Patent:
 - ♦ No significance
- Engagements:
 - ♦ Coordinating Ministry of Economic Affairs
 - Directorate of downstream chemical and pharmaceutical industries (Direktorat Industri Kimia Hilir dan Farmasi), Ministry of Industry
 - Directorate of Pharmaceutical Management and Services (Direktorat Pengelolaan dan Pelayanan Kefarmasian), Ministry of Health
 - Directorate of Pharmaceuticals and Medical Devices Resilience
 - Pharmaceutical Research and Manufacturers of America (PhRMA)
 - Halal Product Assurance Agency (Badan Penyelenggara Jaminan Produk Halal)
 - Chambers of Commerce: Indonesia Chamber of Commerce (KADIN), European Business Chamber of Commerce in Indonesia (EuroCham), American Chamber of Commerce in Indonesia (AmCham), US ASEAN Business Council

Sponsor

M. Idham Hamzah (PT Transfarma Medika Indonesia)

ead

Khoirul Amin (PT Pfizer Indonesia)

Co-Lead

Rizman Abudaeri (PT AstraZeneca Indonesia)

Members

- Marendra Sadikin (PT Merck Sharp & Dohme Indonesia)
 Ferdo Pratama
- (PT Takeda Innovative Medicines)
- **3. Wanda Harahap** (PT Abbott Indonesia)
- 4. Reswita Dery Gisriani
- (PT Glaxo Wellcome Indonesia GSK) 5. Widodo Tri Wibowo
- (PT Novartis Indonesia) 6. Andy Lee
- (PT Johnson & Johnson Indonesia Two) 7. Henny Mansjur
- (PT. B.Braun Indonesia)

48 CHAPTER 02 | IPMG's Task Forces

Photos

01

FGD on the Utilization of Domestic Raw Materials within the Framework of Preparing for the Implementation of the Halal Product Assurance System by the Ministry of Industry of the Republic of Indonesia.

02

Silaturahmi (Friendly/Courtesy) Meeting with Mr. Marzuki Darusman, Senior Political Advisor and Human Rights Campaigner

03

Discussion of the Local Component Requirement Facilitated by the Indonesian Ministry of Health.









TRANSFORMASI INDUSTRI KESEHATAN NASIONAL



04

Industrial Policy Task Force Lead Khoirul Amin Participated in a Public Discussion with the Minister of Health with regards to National Healthcare Industry Transformation.

05

Discussion with Minister of Industry Agus Gumiwang Kartasasmita on the Ministry's policy direction for 2024 – 2029 period

06

PT Menarini Indria Laboratories has successfully obtained the SMK3 certificate, proving the company's commitment to creating a safe and healthy work environment. This certificate is real evidence that the company has met the occupational safety standards set by the government and is ready to compete in an increasingly competitive market.



Market Access (JKN Drug Enlistment) _____

Role and Responsibility

The IPMG JKN Drug Enlistment Task Force plays a key role in enhancing transparency, improving decision-making, and streamlining the BPJS drug enlistment process. By simplifying procurement, the task force aims to improve access to innovative medicines.

A strong healthcare system depends on fair value assessments and HTA programs that do not hinder access to medical technology and innovation. The task force works to prevent inefficiencies and remove barriers to healthcare innovation. By applying best practices, it supports the inclusion of medicines in FORNAS and ensures that HTA and other assessments contribute meaningfully to patient care. This helps policymakers, payers, and healthcare providers make informed, evidence-based decisions that benefit public health.

Key Activities

- Participated in National Formulary Plenary Discussion with Fornas Committee
- Monitored listing Fornas process and gained clarity in procurement system in the consolidated catalog by continued engagement and close follow up on e-catalog system readiness with goods and services procurement bureau.

Sponsor

Evie Yulin (PT Merck Tbk)

Lead

Banarsono Trimandojo (PT Novo Nordisk Indonesia)

Co-Lead

Members

- 1. Dias Bachtiar (PT Johnson & Johnson Two)
- 2. Bram Baan (PT Glaxo Wellcome Indonesia/ GSK)
- 3. Dudit Triyanto
- (PT Merck Sharp & Dohme Indonesia)4. Welly
- (PT Takeda Innovative Medicines) 5. Eko Wahyudi
- (PT Merck Tbk) 6. Ulisis Tarigan
 - (PT Actavis Indonesia)

50 CHAPTER 02 | IPMG'S Task Forces

Photos -

01

IPMG JKN Drug Enlistment Task Force led IPMG delegation in discussion on the consolidated e-Catalog with the Good and Services Bureau of the Ministry of Health.



Market Access (Affordability)

Role and Responsibility

The Affordability Task Force prioritized advocacy efforts on the Coordination of Benefits (CoB), with a particular focus on the top-up scheme for innovative medicines and improvements in the Health Technology Assessment (HTA) process, governance, and capacity building.

To support CoB advocacy, the task force conducted a series of focused group discussions with relevant stakeholders, including Center for Health Financing Policy and Decentralization of the Agency of Health Research and Development and private insurance sector.

In terms of HTA improvements, activities included alignment with the HTA committee and specialized HTA training for IPMG members. The objectives of these efforts were to achieve clarity on HTA positioning, understanding the process between the HTA committee and the Pharmacoeconomic team of National Formulary (Fornas) within the Ministry of Health (MoH) regarding assessment requirements, and simplify the process for new product listings on Fornas. Additionally, the task force aimed to enhance understanding of HTA methodologies for evaluating innovative medicines, value-based pricing adoption, and ensure the smooth implementation of CoB, integrating innovative medicines.

In addition, the task force also serves as the point of contact for relevant ministries on strategic issues related to public access to innovative medicines and vaccines.

Sponsor

Evie Yulin (PT Merck Tbk)

Lead

Andri Kusandri (PT Merck Tbk)

Co-Lead

Danika Kartasasmita (PT Pfizer Indonesia)

Members

- 1. Poppy Widiyani (PT Roche Indonesia)
- 2. Marry Purnama (PT Novartis Indonesia)
- 3. Henny Mansjur (PT B. Braun Indonesia)
- **4. Aulia Citta Arieni** (PT APL)
- Melanitri (PT AstraZeneca Indonesia)

Key Activities

- Actively stimulated discussion and promoted implementation of CoB
- Actively stimulated and promoted discussion on the implementation of HTA institutionalization
- Facilitated an internal health economic workshop in collaboration Center of Excellence for Pharmaceutical Care Innovation (Pharci, Padjajaran University)


Photos –

01

Discussion with the Director General of Pharmaceutical and Medical Devices about Pricing and IPMG's Recommended Solutions to Improve the Availability and Public's Access to Innovative Medicines.

02

Discussion with the Head of the Center for Health Financing Policy and Decentralization of Health Development Policy Agency of the Ministry of Health with regards to Coordination of Benefit and Health Technology Assessment.







52 CHAPTER 02 | IPMG's Task Forces

03

Discussion with Indonesia Private Life Insurance Association





04

Launching of HTA One Stop One Standard



Role and Responsibility

Partnering for Health Advancement Task Force works collaboratively with national stakeholders to build a future where all Indonesians, regardless of location or situation, have access to quality care. The task force focuses on disease prevention, sustainable investment in health, minimizing environmental impact on health, and ensuring affordability. Its objectives include fostering partnerships to create a sustainable and resilient health system and promoting a conducive ecosystem for advancing health and medical technologies.

The task force emphasizes patient-centric innovation, striving to ensure that innovative solutions—spanning products, integrated health solutions, processes, and delivery systems—reach patients as quickly as possible. By prioritizing efficient technology approval and uptake, it aims to enhance healthcare access and outcomes across Indonesia.

Key Activities

• Launched a workable recommendation for the new government through IPMG Manifesto

Sponsor

Dr. Ait-Allah Mejri (PT Roche Indonesia)

_ead

Lucia Erniawati (PT Roche Indonesia)

Co-Lead

Fikriansyah (PT Novo Nordisk Indonesia)

Members

- 1. Khoirul Amin (PT Pfizer Indonesia)
- 2. Reswita Dery Gisriani (PT Glaxo Wellcome Indonesia – GSK)
- **3. Wanda Harahap** (PT Abbott Indonesia)
- 4. Andy Prabowo (PT Novartis Indonesia)

Photos –

01

IPMG Chairman Dr. Ait-Allah Mejri launched IPMG Manifesto at IPMG Stakeholder's Discussion Forum on December 12, 2024



Ethics, Medical,

and Patient Safety

Role and Responsibility

Task Force is dedicated to upholding high ethical, integrity, and professional standards in healthcare business practices. Their mission is to ensure compliance with laws and regulations for the benefit of patients and society. The task force is responsible for promoting ethical conduct in medicine promotion, improving clinical research standards, and prioritizing patient safety.

The task force includes aligning IPMG's Code of Ethics (CoE) with global and local regulations, partnering with stakeholders to promote ethical practices, increasing clinical studies in the country, and supporting internal IPMG stakeholders on ethics, compliance, and patient safety. The future vision is for IPMG to be recognized as a trusted ethical partner in the healthcare sector.

For 2024, the task force has key advocacy priorities, including:

- Ethics & Compliance Reviewing and updating IPMG's CoE, developing an e-learning platform and whistleblower system, providing input to the Ministry of Health (MoH) on regulatory revisions, and participating in anti-corruption events.
- 2. Medical & Patient Safety Strengthening local evidence generation for innovative medicines through collaboration with stakeholders.
- 3. Task Force Operations Budget planning for EMPS meetings throughout the year.

Key Activities

- Reviewed IPMG Code of Ethics and proposed points for improvement
- Facilitated ethical discussions and provided mediation to ensure alignment with the Code of Ethics among members.
- Reinforced IPMG's commitment to ethical business practices and integrity.

Sponsor

- Sreerekha Sreenivasan (PT Novo Nordisk Indonesia)
 Dewi Koesoema
- (PT Astellas Indonesia)

Lead

Emidawati (PT Novartis Indonesia)

Co-Lead

Rospita Dian (PT Johnson & Johnson Indonesia Two)

Members

- 1. Ute Nurdin (PT Mitsubishi Tanabe Pharma Indonesia)
- 2. Aprillia de Leon (PT Roche Indonesia)
- **3. Mayanita Dewi** (PT Takeda Innovative Medicines)
- 4. Elizabeth Luciana
- (PT Glaxo Wellcome Indonesia/ GSK) 5. Hetsa Himawati (PT Merck Tbk)
- **6. Richard Santoso** (Pfizer Indonesia)
- 7. Ratna Indah Widyasari (PT Merck Tbk)
- 8. Mayuresh Fegade (PT Novartis Indonesia)
- **9. Fachriaevi Yanthi** (PT Pfizer Indonesia)
- **10. Febria Rehinatha** (PT AstraZeneca Indonesia)

Photos

01

Ethics, Medical, and Patient Safety Task Force facilitated a meeting to share insights on IPMG Business Practice Ethics



Regulatory Affairs ____

Role and Responsibility

The Regulatory Affairs Task Force is dedicated to advocating for and implementing regulatory initiatives that enhance the efficiency, safety, and sustainability of Indonesia's pharmaceutical regulatory framework. Its primary role is to collaborate with key stakeholders, including the Ministry of Health (MoH) and Indonesia Drug and Food Supervisory Agency, to promote policy changes that recognize international standards. The task force focuses on initiatives such as Indonesia Pharmacopeia harmonization, promoting flexibility to utilize international pharmacopeia monographs and removing Intellectual Property (IP) assessment requirements for innovative drugs.

The task force also leads the implementation of programs like e-labeling to simplify package insert management, supported by budget allocation and detailed timelines to ensure successful adoption. It spearheads knowledge-sharing initiatives, such as joint training sessions on the WHO Collaborative Registration Procedure (CRP), to align local practices with global standards and integrate them into Indonesia's regulatory framework. Additionally, the task force advocates for multi-sourcing policies to strengthen drug supply sustainability, aiming for the inclusion of these policies in regulatory documents like the Brown Book.

Its efforts are geared toward creating a regulatory system that protects public health while fostering a resilient and innovative pharmaceutical industry in Indonesia.

Sponsor

Selly Kartika (PT Abbott Indonesia)

Lead

Desti Wibowo (PT Merck Tbk)

Co-Lead

lin Nurhayati (PT Pfizer Indonesia)

Members

- 1. Anna Emmy Kurniaty (PT AstraZeneca Indonesia)
- 2. Firnando Sianturi (PT Johnson & Johnson Indonesia Two)
- 3. Furqoni C. Mahastika (PT Transfarma Medika Indah)
- 4. Henny Purwantini (PT Boehringer Ingelheim)
- 5. Ervina Dwi Astuti (PT Abbott Indonesia)

Key Activities

- Advocacy for relaxation of Indonesia Pharmacopeia enforcement and to recognize pharmacopeia interchangeability
- E-labelling implementation for medicines to simplify package insert management through electronic labeling implementation
- World Health Organization collaborative registration procedure. Flexibility to register multiple sites to increase resilience and ensure drugs' supply sustainability

Key Stakeholders:

- National Agency of Drug and Food Supervisory Agency
- Directorate general of pharmaceuticals and medical devices
- Commission IX (Health)
- Japan Pharmaceutical Manufacturers Association (JPMA)

Photos

01

Audience on International Pharmacopoeia Recognition with the Secretary of the Directorate General of Pharmaceuticals and Medical Devices



Working Committee Meeting Regarding Supervision of the Drug Safety and Quality Assurance System



7. Enny Utami Wilyani

(PT Novo Nordisk Indonesia)
 8. Marsella Lembayung
 (PT Glaxo Wellcome Indonesia/ GSK)

03

E-labelling Healthcare Practitioner Education Roadshow







04

Courtesy Visit to New Head of National Agency of Drug and Food Supervisors Agency (BPOM)

05

Stakeholder Collaboration and Gathering Commitment by BPOM



CHAPTER 03

IPMG's Vision and Focus in 2025

a.	IPMG Members' Profile	60
b.	Members' Contribution to Indonesia	86
C.	Members' Awards and Recognitions	126



IPMG Members' Profile

PT Abbott Indonesia

Since its establishment in 1971, PT Abbott Indonesia has served the medical community with a broad range of quality healthcare products, and strives to meet the healthcare needs of Indonesian doctors and consumers. We create breakthrough products — in diagnostics, medical devices, nutrition, and established pharmaceuticals — that help you, your family, and your community lead healthier lives full of unlimited possibilities. Commercial operations for PT Abbott Indonesia are headquartered in Jakarta, while manufacturing and warehousing facilities are located in Cimanggis, Depok.



Focus of Therapeutic Areas

- Neuroscience • Cardiovascular
- Pediatrics
 Vaccines
- Vitamin
- Women's Muscle Health
- Vitamins

Contact Us

Pondok Indah Office Tower 2, Suite 1000, JI. Sultan Iskandar Muda Kav. V-TA, Jakarta 12310, Indonesia **Telephone:** +62 21 2758 7888

Website: www.abbott.co.id




PT Actavis Indonesia

Enabling Access to High Quality Medicines and Health Solutions

PT Actavis Indonesia is part of Actavis Generics, a global pharmaceutical company focused on developing, manufacturing, and commercializing branded pharmaceuticals, generic and OTC medicines, and biological products.

Our portfolio consists of best-in-class products that provide valuable treatments for the central nervous system, respiratory, gastroenterology, cardiovascular, oncology and anti-infective therapeutic categories, which provides patients around the globe with increased access to affordable, high-quality medicines. Our R&D focuses on the development of innovative and durable, valueenhancing products within brands, generics, biologics, and OTC portfolios.

We are committed to increasing access to quality health solutions and to have an unparalleled impact on patients and healthcare systems worldwide.



Focus of Therapeutic Areas

- Nervous System
- Systemic Anti-Infectives
- Consumer Health
- OTC
- Cardiovascular System
- Musculoskeletal
- G. U. System
- Respiratory
- Oncology
- Dermatology

Contact Us

Jl. Raya Bogor Km. 28, Jakarta 13710, Indonesia

Telephone: +62 21 871 0311 **Fax:** +62 21 871 0044

Website: www.actavis.co.id



PT Anugerah Pharmindo Lestari (APL) Member of Zuellig Pharma

PT Anugerah Pharmindo Lestari (APL), a member of Zuellig Pharma, has been successfully serving the Indonesian healthcare market since 1985. APL was founded by DR. Biantoro Wanandi's dream of having a world-class distribution company in Indonesia. Our main purpose is to make healthcare more accessible to the community we serve. We provide world class distribution, commercial, and digital and data analytics services to support the growing healthcare needs across the complex geography and multi-channel environment of Indonesia. Our people serve over 60,000 medical facilities in 434 cities and work with over 60 clients, including the top 10 pharmaceutical companies in the world. We operate a state-of-the-art national distribution center, a regional distribution center, and 25 pharma-grade warehouses.

At APL, we are dedicated to building a healthier future for Indonesia through our sustainability vision, which is rooted in four key pillars. We improve health outcomes by collaborating with our stakeholders, nurturing talent through education and professional growth, respecting the environment by adopting sustainable practices, and setting the highest integrity standards in all our operations. Our integrated approach not only supports but also strengthens the communities we serve in Indonesia, paving the way for a resilient and sustainable future.

Pain Management

• Women's Health

Immunology



Focus of Therapeutic Areas

- Oncology
- Diabetes
- Hypertension
- Cardiamatak
- Cardiometabolic
 - tabolic
- Cough and Cold/CHC

Contact Us

World Trade Center (WTC) 1, 15th Floor Jl. Jenderal Sudirman Kav. 29-30, Jakarta 12920 **Telephone:**

+62 21 2168 4084

Fax: +62 21 2168 4085

Email: info@aplcare.com



PT Astellas Pharma Indonesia

PT Astellas Pharma Indonesia was established in 2000 as PT Yamanouchi Indonesia, a subsidiary of Yamanouchi Pharmaceutical Co., Ltd., a pharmaceutical company based in Japan. On April 1, 2005, Astellas Pharma Inc. was established through a merger of Yamanouchi Pharmaceutical Company Limited and Fujisawa Pharmaceutical Company Limited. Following this merger, PT Yamanouchi Indonesia changed its name to PT Astellas Pharma Indonesia.

Focus of Therapeutic Areas

- Urology
- Oncology
- Transplantation

Contact Us

Plaza Oleos, 5th Floor Jl. TB Simatupang No. 53A, Jakarta Selatan 12520, Indonesia **Telephone:** +62 21 2278 0171

Website: www.astellas.com



63



PT AstraZeneca Indonesia

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases. The Company is also active in inflammation, infection and neuroscience through numerous collaborations.

Focus of Therapeutic Areas

- Oncology
- CVRM (Cardiovascular, Renal, Metabolism)
- RIVI (Respiratory & Immunology, Vaccines and Immune
- Therapies)
- Rare Disease

Contact Us

Perkantoran Hijau Arkadia Jl. TB Simatupang Kav. 88 Tower G, 16th Floor Kebagusan, Ps. Minggu, South Jakarta, Jakarta 12520, Indonesia **Telephone:** +62 21 2997 9000

Website: www.astrazeneca.com



AstraZeneca

Headquarter Cambridge, United Kingdom

PT Bayer Indonesia

Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. In line with its mission, "Health for all, Hunger for none," the company's products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability, and quality throughout the world. In fiscal 2024, the Group employed around 93,000 people and had sales of 46.6 billion euros. R&D expenses amounted to 6.2 billion euros. For more information, go to www.bayer.com.

Bayer in Indonesia

Bayer has been present in Indonesia since 1920, and officially established PT Bayer Indonesia in 1957. Bayer operates through three core divisions—Pharmaceuticals, Consumer Health, and Crop Science—supported by enabling functions. Indonesia is home to three Bayer supply centers, key contributors to the global manufacturing network, with products serving both domestic and international markets. Our people—driven by passion, expertise, and a spirit of continuous improvement are the foundation of our success as a world-class innovation company.



Focus of Therapeutic Areas

- Cardiovascular
- Women's
- Healthcare
- Ophthalmology
- Anti-allergy

- Cancer
- Oncology

- Radiology

- Nutritions

Contact Us

Menara Astra, 33rd Floor II. lend. Sudirman Kav. 5-6. Jakarta 10220, Indonesia

Telephone: +62 21 3049 1111

Fmail: contact.indonesia@bayer.com

Website www.bayer.com



B. Braun Indonesia (PT B. Braun Medical Indonesia & PT B. Braun Pharmaceutical Indonesia)

B. Braun Indonesia has established itself as a leading medical technology and pharmaceutical company since entering the Indonesian market in the 1980s. With over 35 years of experience, the company has continually evolved to meet the changing needs of the healthcare industry. This commitment to innovation is exemplified by the establishment of a state-of-the-art pharmaceutical factory in Karawang, West Java, in 2017, leading to the formation of two distinct entities: PT B. Braun Medical Indonesia and PT B. Braun Pharmaceutical Indonesia. This expansion reflects B. Braun Indonesia's dedication to providing cutting-edge medical products and solutions.

Leveraging the 180-year heritage and global network of B. Braun Melsungen AG, with a presence in over 60 countries, B. Braun Indonesia combines global expertise with local market understanding. The company is committed to sharing its knowledge through innovative training concepts, including the Aesculap Academy medical training center in Tabanan, Bali. B. Braun Indonesia strives to be a preferred partner for its customers by offering comprehensive treatment concepts, smart healthcare business solutions, and a steadfast commitment to its mission: protecting and improving the health of people in Indonesia and around the world.

Headquarter Melsungen, Germany

B BRAUN

Focus of Therapeutic Areas

- Minimally Invasive Surgery
- Conventional Surgery
- Oncology
- Pain Therapy
- Dental Care
- Infusion Therapy
- Neurosurgery
- Extracorporeal Blood Treatment Therapies
- Coronary and Peripheral Vascular Disease
- Wound Care Management

Contact Us



PT Boehringer Ingelheim Indonesia

Boehringer Ingelheim is a biopharmaceutical company active in both human and animal health. As one of the industry's top investors in research and development, the company focuses on developing innovative therapies that can improve and extend lives in areas of high unmet medical need. Independent since its foundation in 1885, Boehringer takes a long-term perspective, embedding sustainability along the entire value chain. More than 53,500 employees serve over 130 markets to build a healthier, more sustainable, and equitable tomorrow. Learn more at www.boehringeringelheim.com

Focus of Therapeutic Areas

- Metabolic
- Cardiovascular
- Respiratory
- Oncology
- Specialty

Contact Us

Sequis Tower, Level 22 Unit 5 Jl. Jend. Sudirman Kav. 71, South Jakarta 12190, Indonesia





IPMG ANNUAL REPORT 2024

PT Daewoong Pharmaceutical Company Indonesia

Daewoong Pharmaceutical is a prominent South Korean pharmaceutical group with a growing presence in Indonesia, having its Indonesian subsidiary Daewoong Pharmaceutical Company Indonesia (DPCI), established in 2005. DPCI is the holding company of Daewoong's business in Indonesia that manages Daewoong Biologics Indonesia (DBI), CGBio Neoregen Indonesia (CNI) and Selatox Bio Pharma. The company has established itself as a key player in the Indonesian healthcare market by offering a range of high-quality pharmaceutical products, including prescription medications, over-the-counter (OTC) drugs, and health supplements. Daewoong Pharmaceutical is known for its commitment to research and development (R&D), with a focus on creating innovative and effective treatments across various therapeutic areas, including gastroenterology, cardiology, neurology, and oncology.

In Indonesia, Daewoong has leveraged its global expertise to meet local healthcare needs, building strong partnerships with distributors, healthcare professionals, and regulatory bodies. This strategic approach has allowed the company to expand its footprint in the competitive Indonesian market.

Additionally, Daewoong Pharmaceutical is recognized for its emphasis on corporate social responsibility (CSR). The company has undertaken several initiatives aimed at improving public health in Indonesia, supporting local communities, and promoting sustainable healthcare practices.

Daewoong's operations in Indonesia are part of its broader vision to become a leading global healthcare provider, contributing to the advancement of medical science and the well-being of populations worldwide.



Focus of Therapeutic Areas

- Gastrointestinal Diseases
- Orthopedic
- Endocrine
- Cardiovascular

Stem Cell Therapy Rare Diseases

- Aesthetics
- Aesthetics

Contact Us

Wework Revenue Tower 26th, SCBD, Jl. Jenderal Sudirman No.52-53, RT.5/RW.3, Senayan, Jakarta, South Jakarta City, Jakarta 12190





MANUFACTURING SITES



PT Eisai Indonesia

In 1968, the company established marketing operations in Indonesia, and by 1970, it was established as PT Eisai Indonesia. We developed our plantation research facility in Tjianjur in 1976, then moved to Citeureup in 1987 until the present day. 1989 saw the first export to Japan. By 1990, we had expanded exports to Thailand. Eisai has a very strong philosophy: when conducting business in human health care (HHC), it reflects our commitment to activities that increase benefits for patients, their families, and consumers.

Focus of Therapeutic Areas

- Oncology
- Neurology
- Gastrointestinal

Contact Us

Trinity Tower 10th floor, Suites 09-15 Jl. HR Rasuna Said No.6. Karet Kuningan, Setiabudi Jakarta 12940



PT Glaxo Wellcome Indonesia (GSK)

GSK is a global biopharma company with a presence in Indonesia. We have been here in Indonesia for more than 50 years and has manufacturing facility established since 1994. As a company, our purpose is to unite science, technology, and talent to get ahead of disease together. We are deeply committed to positively impacting the health of 2.5 billion people by the end of the decade. In Indonesia, we engage with patients and their healthcare providers to understand the impact of disease and drive innovation that makes a difference where it matters most.

At GSK, we prioritize the well-being of society and the sustainability of our company, addressing issues such as access to healthcare and contributing to the health of our planet. Our culture, centered around being ambitious for patients, accountable for our impact, and doing the right thing, drives our strategy and ensures that we deliver for patients, shareholders, and GSK people.

Focus of Therapeutic Areas

Respiratory (Asthma, COPD, Rhinitis Alergic) and preventive options of infectious disease at every stage of life, such as shingles, RSV, flu, dtap, Hepatitis, rotavirus and many more.

Contact Us

RDTX Square 19th Floor Jl. Prof. Dr. Satrio, No. 164, Setiabudi, Jakarta 12930, Indonesia

Telephone: +62 21 2553 2350 Email: cga.indonesia@gsk.com

Website www.gsk.com



GSK



Johnson &Johnson

> Headquarter New Jersey, USA

PT Johnson and Johnson Indonesia Two


PT Johnson and Johnson Indonesia Two (also known as PT Johnson & Johnson Indonesia) is the local operating company of Johnson & Johnson, the world's largest and most broadly-based healthcare company. Established in Indonesia in 1973, the company engages in three business sectors: consumer health, pharmaceuticals, and medical technology (including Vision).

Focus of Therapeutic Areas

- Oncology
- Immunology
- Pulmonary HypertensionPain Management
- Neuroscience (Psychiatry & Neurology)
- Infectious Diseases & Vaccines

Contact Us

WeWork – Revenue Tower 27th Floor, Jl. Jend. Sudirman Kav. 52-53, SCBD Lot 13 Jakarta Selatan



71

PT Transfarma Medica Indah (Menarini Indonesia)

Menarini Indonesia is part of Menarini Group, the world's largest Italian biopharmaceutical company with a heritage of over 128 years and over 16,000 employees in over 100 countries. Founded in 1886, it is privately owned and headquartered in Florence, Italy.

Menarini Indonesia's vision is to be a leading provider of important healthcare brands to improve the lives of people in Indonesia. Menarini Indonesia operates across the entire commercial value chain, from regulatory approval and product launch to lifecycle management with a diverse portfolio of proprietary and partnered brands in key therapeutic fields, including cardio-metabolic, allergy/ respiratory, gastroenterology, central nervous system, consumer healthcare, pain management, dermatology, and oncology. Commercial operations for Menarini Indonesia are headquartered in Jakarta, while manufacturing and warehousing facilities are located in Cikarang, Jawa Barat.

Focus of Therapeutic Areas

- Cardio-metabolic
- Allergy/Respiratory
- Gastroenterology
- Central Nervous System
- Consumer Healthcare
- Pain Management
- Dermatology
- Oncology

Contact Us

Pondok Indah Office Tower 2, 8th Floor Jl. Sultan Iskandar Muda RT 4 RW 3 Pd. Pinang Kec Kebayoran Lama, South Jakarta





PT Meiji Indonesia

PT Meiji Indonesia has pioneered high-quality antibiotics since its foundation in 1974. Initially a subsidiary of Japan-based Meiji Seika Kaisha Ltd. (now operating as Meiji Seika Pharma Co., Ltd.), PT Meiji Indonesia is one of the few players in the pharmaceutical sector, delivering the highest quality production standards in Indonesia. After more than four decades of helping to improve the nation's health, PT Meiji Indonesia looks forward to the decades ahead.

Focus of Therapeutic Areas

- Antibacterial
- Osmotic Laxative
 - Gastrointestinal Disorder
- Lipid Regulator .

Ophthalmology

Contact Us

Jl. Prof. Dr. Soepomo No. 40, Tebet Jakarta Selatan 12870, Indonesia

Telephone: +62 21 2138 3388 Website www.meiji.co.id



m

F

Meiji Indonesia



PT Merck Tbk (Merck Indonesia)

PT Merck Tbk is an affiliate of Merck KGaA, Germany ("Merck"). Merck is a vibrant science and technology company with 356 years of global footprint. Science is at the heart of everything we do. It drives the discoveries we make and the technologies we create. We make a positive difference to millions of people's lives every day. Our constant curiosity and specialist approach drive our partnerships and bring new ideas to life, from advancing gene editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices. Our work is fueled by our belief in science as a force for good. We work to enhance the human experience and create more joyful and sustainable ways to live.

We believe scientific exploration and responsible entrepreneurship are key to technological advances that benefit us all. This is how Merck has thrived since 1668. We will continue to push the boundaries of possibility to create opportunities for everyone. This is what drives us. This is what we work for. This is our future.

In Indonesia, Merck was established on October 14, 1970, and transformed into a public company in 1981. PT Merck Tbk runs Merck's healthcare business and focuses on discovering, developing, manufacturing, and marketing innovative prescription medicines. For more than 50 years, we have existed in Indonesia and maintained our focus on patient lives. The transformation has strengthened our focus in the changing world, re-emphasizing our respect toward life and our responsibility to improve the quality of life.



Focus of Therapeutic Areas

- Oncology
- Multiple Sclerosis
- Fertility
- Growth Hormone
 Deficiency
- Diabetes
- Cardiovascular Diseases
- Thyroid Disease
- General Medicine Treatments
- Advanced Fertility Technologies and Devices

Contact Us

Arkadia Green Park, G Tower, 9th Floor, Jl. TB Simatupang Kav.88, Kebagusan, Pasar Minggu, South Jakarta 12520

Manufacturing Site: Jl. TB Simatupang No.8, Pasar Rebo, Jakarta Timur - 13760



PT Merck Sharp & Dohme Indonesia (MSD Indonesia)

Merck & Co., Inc. New Jersey (NJ), United States (US) was founded on January 1, 1891. George Merck, age 23, established the company in the US to distribute fine chemicals throughout New York City and its neighboring areas. Outside of the US and Canada, Merck & Co., Inc., New Jersey, US is known as Merck Sharp & Dohme (MSD).

MSD aspires to be the premier research-intensive biopharmaceutical company. We're at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals.

For more than 130 years, we brought hope to humanity through the development of important medicines and vaccines. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. Our purpose: We use the power of leading-edge science to save and improve lives around the world.

We're a global health care company working to deliver innovative health solutions through our medicines, vaccines, biologic therapies and animal health products. We're focused on discovering new solutions for today and the future. From finding solutions for some of the world's most debilitating diseases, to getting our medicines and vaccines to those in need and building more effective health systems, we're always on a mission to create a better world.

MSD is a trade name of Merck & Co., Inc., with headquarters in Kenilworth, New Jersey, the US. PT Merck Sharp & Dohme Indonesia was established in 2005 and currently focuses on our main therapeutic areas, namely oncology, and vaccines.

Focus of Therapeutic Areas

Oncology & Vaccines

Contact Us

Wisma BNI 46, 27th Floor, Jl. Jend. Sudirman Kav. 1, Jakarta 10220, Indonesia







PT Mitsubishi Tanabe Pharma Indonesia

We opened our doors in Indonesia on Saturday, July 25, 1970, under the company name of PT Tanabe Abadi, a joint-venture between Tanabe Seiyaku Co., Ltd., Osaka, Japan and N.V. Pharmacie Nasional, Bandung, Indonesia. PT Tanabe Abadi began its commercial production at the manufacturing site located on Jl. Dr. Setiabudi, Bandung.

To increase production capacity and maintain product quality, we decided to relocate the manufacturing site to the current Jl. Rumah Sakit, Ujungberung, Bandung on March 29, 1986.

With the change in capital structure and the aim of expanding the business network, on June 1, 2003, the company name was changed to PT Tanabe Indonesia.

On October 1, 2007, the holding company Tanabe Seiyaku Co., Ltd. merged with Mitsubishi Pharma Corporation and formed the newly named Mitsubishi Tanabe Pharma Corporation. On October 1, 2018, the company name was changed to PT Mitsubishi Tanabe Pharma Indonesia.

As a subsidiary of Mitsubishi Tanabe Pharma Corporation, Osaka, Japan, we are engaged in the pharmaceutical industry with a business focus on producing and selling ethical products for domestic and overseas markets. We do our utmost to contribute to Indonesian society and to improve the quality of life of the Indonesian people by supplying them with our high-quality products.

Antipsychotics

Nervous System



Focus of Therapeutic Areas

- Cardiovascular
- Metabolism
- Immuno-inflammatory
- Anesthetics

Contact Us

Jl. Tanah Abang III No. 8, Kelurahan Petojo Selatan, Kecamatan Gambir, Central Jakarta 10160, Indonesia

Telephone: +62 21 3841 842 Website: www.mt-pharma-id.com



PT Novartis Indonesia

Novartis has been serving Indonesian patients for more than 50 years, through our predecessor companies, Ciba and Sandoz. Novartis is a global healthcare company based in Basel, Switzerland, with a history going back more than 150 years. We provide healthcare solutions that address the evolving needs of patients and societies worldwide.

Our purpose is to reimagine medicine to improve and extend people's lives. We use innovative science and technology to address some of society's most challenging healthcare issues. We discover and develop breakthrough treatments and find new ways to deliver them to as many people as possible.

Novartis has been serving Indonesian patients for more than 50 years, through our predecessor companies, Ciba and Sandoz. Under one legal entity of PT Novartis Indonesia, we continue to provide our innovative medicines to Indonesian patients and demonstrate our commitment in improving the healthcare system in Indonesia through public private partnerships.

Novartis Indonesia Head Office is located in AXA Tower, Kuningan, Jakarta, while our factory/site is located in Pasar Rebo, Jakarta.



Focus of Therapeutic Areas

Cardiovascular and Oncology

Contact Us

AXA Tower 26th Floor, Kuningan City Jl. Prof. Dr. Satrio Kav. 18, Kuningan, Setiabudi, South Jakarta 12940 Indonesia



PT Novo Nordisk Indonesia

Novo Nordisk is a global healthcare company from Denmark with more than 100 years of innovation and leadership in healthcare. Our purpose is to drive change to defeat serious chronic diseases.

We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure the diseases we treat.

In Indonesia, we have been translating the unmet medical needs of people living with a serious chronic disease into innovative medicines. Our treatments benefit patients living with diabetes and rare diseases.

We have been working closely with the Indonesian MoH since the beginning of our establishment in Indonesia. Novo Nordisk has also been appointed as the implementing partner for the Indonesian MoH and the Danish MoH's joint action plan to address diabetes and chronic disease prevention and management in Indonesia since 2021. As the implementing partner, Novo Nordisk has started several programs to address the issue, e.g. Affordability Project, Changing Diabetes in Children, and Tanya Gendis – a diabetes chatbot. Furthermore, we have organized numerous awareness activities, annually during World Diabetes Day and World Obesity Day.

Novo Nordisk also supports the government's efforts to enhance public health and address affordability. All of Novo Nordisk's insulin and hemophilia products are listed in JKN, Indonesia's universal health coverage, allowing the company to serve people at all levels of the economic scale.



Focus of Therapeutic Areas

- Diabetes
- Hemophilia
- Growth Disorder

Contact Us

Pondok Indah Office Tower 5, 20th Floor Suite 2004-0 Jl. Sultan Iskandar Muda Kav V-TA, Pd. Pinang, Kec. Kby. Lama South Jakarta 1231, Indonesia

Telephone: +62 21 2958 1000 e-Mail: NNIDContactUs@novonordisk.com

Website: www.novonordisk.id



PT Organon Pharma Indonesia Tbk

Organon is an independent global healthcare company with a strategy to improve the health of women throughout their lives. Our diverse portfolio across women's health, biosimilars, and established brands includes therapies and products for a wide range of conditions and diseases.

Our portfolio encompasses more than 60 medicines and devices across a range of areas including reproductive health, cardiovascular disease, neurology, autoimmune, and respiratory conditions. We bring these important therapies to more than 150 markets around the world.

Focus of Therapeutic Areas

• Women's Health

Contact Us

Sinarmas MSIG Tower Lv. 37, Jl. Jend. Sudirman Kav. 21 Setiabudi, South Jakarta, DKI Jakarta 12920



- ORGANON

79



PT Otsuka Indonesia

PT Otsuka Indonesia was established in 1974 as a joint venture pharmaceutical company with Otsuka Pharmaceutical Co., Ltd., Japan. Built on an area of 48,397 square meters in Lawang, a small town in East Java, PT Otsuka Indonesia manufactures and markets medicinal products, such as infusion/injection fluids and ethical drugs, nutritional products for special medicinal purposes, as well as medical devices.

This step of business diversification undertaken by PT Otsuka Indonesia is constantly growing, not only in Indonesia. We have also expanded our production by exporting products to many countries, such as Hong Kong, Singapore, Malaysia, Myanmar, Vietnam, the Philippines, Mongolia, Sri Lanka, Thailand, India, and Egypt.

For decades, PT Otsuka Indonesia has proven itself to be the leader in the infusion solution business. To strengthen our position, we continue to challenge ourselves to develop new products that will fulfill customer needs in the future, based on our motto, "Otsukapeople creating new products for better health worldwide."



Focus of Therapeutic Areas

- CNS
- Cardiovascular
- Oncology
- Clinical Nutrition
- I.V. Solution
- Contact Us

Pondok Indah Office Tower I, 6th Floor Jl. Sultan Iskandar Muda Kav. V-TA. Pondok Pinang, Kebayoran Lama, South Jakarta 12310, Indonesia



PT Pfizer Indonesia (Pfizer Indonesia)

Pfizer began operations in Indonesia in 1969 when the company employed only 11 employees under the auspices of Pfizer International (Pfizer Inc.). As the business grew, Pfizer Indonesia inaugurated its first manufacturing facility in 1971, highlighting the commitment to advance Indonesia's pharmaceutical industry. For more than 50 years, Pfizer Indonesia has strived to promote Indonesia's health sector's advancement through the prevention, treatment, and cure of various diseases.

Currently, Pfizer Indonesia operates as a manufacturing facility that produces various medical drugs to meet domestic and neighboring countries' needs. Supported by more than 300 employees, Pfizer Indonesia provides medicines and health solutions at every stage of life. The company's supply chain has been recognized for implementing good manufacturing practices, showcasing good production methods and environmental management advantages. Through the Pfizer Global Supply Business Unit, Pfizer Indonesia manufactures and exports products in the form of tablets, capsules, and ointments with various brands to South Korea, Malaysia, Singapore, Thailand, the Philippines, Vietnam, Brunei, and Hong Kong.

Pfizer Indonesia has set the standards for high-quality and safe medicines and vaccines. The company has been working with healthcare providers, government agencies, and local communities to expand access to various innovative therapeutics. Pfizer Indonesia has partnered with patient groups and an innovative startup in launching the first digital patient assistance program in Indonesia, also continuously collaborating with health practitioners in supporting local and global initiatives for broader and better access to quality drugs and treatments for patients.



Focus of Therapeutic Areas

- COVID-19 Therapies
- Pneumonia Vaccine
- Oncology
- Hospital Products (including anti-infectives and pain management)
- Rare Disease Treatment Immunology & Inflammation
- Contact Us
- World Trade Center 3, 28th Floor Jl. Jenderal Sudirman Kav. 29-31, Jakarta 12920, Indonesia
- **Telephone:** +62 21 8086 1400
- Website: www.pfizer.co.id



PT Roche Indonesia (Roche Indonesia)

Throughout our 125-year history, Roche has grown into one of the world's largest biotech companies, as well as a leading provider of in-vitro diagnostics and a global supplier of transformative innovative solutions across major disease areas, including oncology, neurology, infectious diseases, and ophthalmology. With our combined strengths in pharmaceuticals and diagnostics, we are better equipped to drive personalised healthcare forward-to bring the right treatments to the right patients at the right time.

For more than 50 years in Indonesia, we continue to focus on helping patients in Indonesia live longer, better lives through prevention, diagnostics and treatment as well as make a sustainable contribution to the nation.

Focus of Therapeutic Areas


- Oncology
- Antiviral
- Ophthalmology
- Parkinson's Disease
- Rare disease
- Rare disease
- Immunosuppressant
 - Hematology

Contact Us

AIA Central Building, Lantai 35 Jl. Jend. Sudirman Kav. 48 A, Jakarta 12930, Indonesia

Telephone: +62 21 3041 3000





PT Servier Indonesia (Servier Indonesia)

Servier is an independent group committed to therapeutic progress, serving patient needs and governed by a non-profit foundation. Currently, there are 150 countries, including Indonesia, in which the group's medicines are distributed.

In 1987, PT Parvico Bersaudara was established to promote Servier products. PT Servier Indonesia was legally founded in 2005. The group strongly believes that working with patients at all stages of the medicine's life cycle leads to better care and solutions to support them throughout their journey.

Focus of Therapeutic Areas

- Cardiometabolism
- Neuroscience
- Immuno-inflammation
- Oncology

Contact Us

Menara Kadin Indonesia, 18th Floor, Jl. R. H. Rasuna Said Blok X-5 Kav 2-3, RT.1/ RW.2, Kuningan, South Jakarta 12950, Indonesia



83




Takeda Indonesia (PT Takeda Innovative Medicines & PT Takeda Indonesia)

At Takeda, creating Better Health for People and a Brighter Future for the World is our purpose. Our values have guided us throughout our over 240 year long history and our ambition remains steadfast. We strive to deliver truly transformative treatments, contributing significant value to society while building an exceptional experience for our people.

Our vision is to discover and deliver life-transforming treatments guided by our commitment to patients, our people, and the planet. This purpose-led and values-based approach is a core foundation of our global growth strategy and long-term value creation for our stakeholders. In our pursuit of global R&D and the country's strategy, we are unwaveringly committed to tackling the most pressing unmet medical needs and overcoming the most formidable challenges in public health.

At Takeda, accelerating patient access to medicines and vaccines is ingrained in our company values. We believe broadening access to our life-changing medicines and vaccines in underserved communities requires an integrated, sustainable approach that mobilizes collective efforts. By partnering with diverse stakeholders, we are actively addressing barriers to access and strengthening healthcare systems to improve lives worldwide.

In Indonesia, Takeda has contributed to the country's healthcare improvement for more than 50 years, since 1971, covering a broad set of expertise including oncology, gastroenterology, rare diseases, vaccines, and consumer healthcare. We are dedicated to expanding access to our innovative treatments for more patients in Indonesia, fostering enduring partnerships with diverse stakeholders to enhance patient outcomes and sustain the healthcare system in the long term. Our head office is located in Jakarta, with a manufacturing plant in Bekasi, West Java.



Focus of Therapeutic Areas

- Oncology
- Gastroenterology
- Rare Disease
- Plasma Derived Therapy
- Vaccine Primary Care
- Consumer Healthcare
 - Lonsumer Healthcare

Contact Us

RDTX Place – 18th floor Jl. Prof. DR. Satrio Kav. 3, RT 17 / RW 04, Kuningan, South Jakarta, Indonesia

Telephone: +62 21 8665 9400 Website: www.takeda.com/id-id/



W

PT Wellesta CPI Healthcare

Wellesta Indonesia is a healthcare company headquartered in Singapore. It has operated in Indonesia since 2019. We aim to serve clients and consumers through commercial and marketing support using an innovative approach across the Wellesta value chain. Working at full compliance and transparency is our approach to doing business.

Focus of Therapeutic Areas

- Neuroscience
- Nephrology
- PediatricsOncology
- Primary Care
- Contact Us

Kirana Three Office Tower, 8th Floor Jl. Boulevard Raya Kav. 1, Kelapa Gading Timur, North Jakarta 14240, Indonesia

Website: www.wellesta.com



Wellesta cpi



Members' Contribution to Indonesia



Shaping Tomorrow: APL Mengajar Leads the Way in Health and Sustainability Education In 2024, APL Mengajar is transforming the future of Indonesia's youth by empowering up to 1,500 students across 10 cities with vital life skills, including Jakarta, Bandung, Bogor, Palembang, Pekanbaru, Bandar Lampung, Banjarmasin, Samarinda, Semarang and Surabaya. Through volunteer-led education in underserved schools, the program focuses on hygiene and waste management, providing students with practical knowledge that directly impacts their health and environment.

By teaching habits like proper handwashing and clean living, APL Mengajar helps combat public health challenges. The waste management component educates students on reducing waste, recycling, and creating eco-enzyme solutions from fruit peels, fostering environmental responsibility.

In partnership with Merck (Indonesia) and involvement of Bapanas (National Food Agency), APL Mengajar aligns with Indonesia's 2045 vision and the UN's SDG #4 for Quality Education. The program's ripple effect extends beyond classrooms, creating a health-conscious, eco-aware generation.

APL Mengajar is not just educating—it's shaping Indonesia's sustainable future, one student at a time.

Improving Health Outcomes Through Knowledge Sharing: Medtalk by APL In line with APL's commitment to promoting health awareness and well-being, Medtalk stands as a flagship initiative dedicated to educating and empowering employees on essential health topics. This monthly event has successfully engaged over 1,750 employees across various work locations, providing a dynamic platform for sharing valuable health information and fostering meaningful discussions.

Covering a wide range of health concerns—from stroke and erectile dysfunction to GERD, diabetes, and emerging issues like monkeypox—Medtalk equips employees with practical insights to make informed health decisions. By incorporating expert perspectives, the program ensures the delivery of reliable, actionable advice, amplifying its positive impact.

In 2024, Medtalk further expanded its reach by partnering with ZP Therapeutics to host a hybrid session on Diabetes Day. This event brought together more than 12 healthcare professionals (HCPs) to share insights on diabetes prevention, management, and the latest innovations in treatment. This collaboration highlights APL's proactive stance in tackling critical health issues while creating an inclusive environment for learning.

Additionally, APL has partnered with The Indonesian Pharmacists Association to offer a series of webinars through eZEducation. This platform has become a cornerstone for advancing professionalism and enhancing pharmacy practice standards in Indonesia by providing innovative, reliable, and accessible educational content. In 2024, over 1,500 apothecaries participated in the webinar series covering topics such as asthma, cardiovascular health, cancer, and more.



In June 2024, AstraZeneca Indonesia and the Ministry of Health sealed a Collaborative Agreement as part of joint effort in improving Indonesia's healthcare system for Non Communicable Diseases (NCD). This agreement was signed by Eva Susanti, the Director of NCD of the Ministry of Health and Esra Erkomay, Country President of AstraZeneca Indonesia (AZI). Through this Agreement, AZI was able to further strengthen its position to unlock the barrier to healthcare access.



In 2024, AstraZeneca Indonesia held GP Capability Training in three different cities, Jakarta, Yogyakarta, and Bandung. Through this event, we managed to provide training to 700+ primary care.



IPMG's Vision and Focus in 2025 | CHAPTER 03

89

In December 2024, Esra Erkomay, Country President of AstraZeneca Indonesia, was invited to be one of the panelists at the Sweden-Indonesia Sustainability Partnership (SISP) Healthcare Conference 2024 themed "Celebrating Co-creation. Shared challenges are best solved together". This event has opened up an in-depth discussion on the use of co-creation to address challenges faced in the health sector. Through this opportunity, not only does it highlight AZI's contribution to improving patient health, but it can also be a forum to find ways to help stakeholders in creating equitable access to health services.

AstraZeneca Indonesia and Indonesian Urologists Association (InaUA) has signed a MoU in strengthening the ecosystem and awareness on prostate cancer screening. This collaboration is expected to advance the services of healthcare in Indonesia. Hotthore and a second s



In 2024, AstraZeneca Indonesia held GP Socialization on Lung Cancer Screening with MoH. Through this event, we managed to provide training to 300+ primary care.

General Practitioners Socialization and Screening with the Ministry of Health The Young Health Program (YHP) has educated over 20 million people on noncommunicable diseases and, through the Girls Take Over initiative, fosters leadership in youth, especially girls. The GTO program is a collaborative program between AstraZeneca and Plan International to promote modern female leadership by giving them a chance to lead cross-functional meetings and engage in discussion surrounding the topic of diversity and health.



AZI joined the Indonesia International Sustainability Forum for two years as the sole pharmaceutical. In 2024, AstraZeneca Indonesia was appointed as a Thematic Partner at the Indonesia International Sustainability Forum (IISF) 2024 hosted by the Coordinating Ministry for Maritime and Investment. AstraZeneca also signed an MoU with the West Java Government in this year's event to support the AZ Forest initiative, our flagship sustainability program to protect the environment and local communities.

Memorandum of Understanding Signing with West Java Government



The Cimanggis plant leads Indonesia's multinational pharma industry in green energy with a 1.66-hectare, 2,054 kWp rooftop solar installation (3,770 modules, 43% of capacity). Achieving 17.8% site energy efficiency, it reduces carbon emissions by 2,073 metric tons annually (equivalent to 95,000 trees or 450 cars). Inaugurated by EU Ambassador Denis Chaibi and Indonesian government stakeholders on November 14, 2024.

Bayer's CETING initiative, aimed at combating stunting, has made a significant impact on 2,300 Depok residents. As part of their factory's dedication to community health, Bayer Cimanggis implemented the program to improve access to essential resources like clean water and health education. This effort, which included the creation of communal water stations and training for community members, ultimately provided clean water to 150 households and targeted over 500 women and girls with vital health information.



Sustainability: Green Energy

Transformation - Cimanggis

Plant's 1.66 Ha Solar Array

In 2024, Bayer furthered its long-standing support for local Posyandu (Integrated Health Posts) by implementing a revitalization program. This initiative included both physical improvements, through building renovations, and educational enhancements, via health training for the Posyandu cadres



As a component of its ongoing Posyandu development, Bayer, in collaboration with FKM UI, implemented an urban farming training program in 2024. This promotes sustainable food practices within the community, offering both nutritional benefits and potential economic opportunities.



Bayer and Reach52 partnered in Indonesia to conduct health education focused on nutrition, maternal and child health, successfully engaging more than 9,000 women in farming communities in Serang, Pandeglang, and East Nusa Tenggara.



93

BBRAUN

B. Braun Indonesia launched a 1.2 MWP solar power plant at its Cikampek factory in Karawang, West Java, on January 18, 2024. This initiative supports the Indonesian government's goals of achieving a 23% renewable energy mix by 2025 and netzero emissions by 2060, while also reducing carbon emissions.

1.2 MWP Solar Power Plant Launching

B. Braun Indonesia's solar power plant is part of the company's commitment to renewable energy and its transition to cleaner energy sources. The plant will supply electricity to its various facilities, including production areas. Generating 1,673 gigawatt-hours (GWh) of electricity annually, it will cover approximately 20-30% of the B. Braun Indonesia factory's electricity consumption.

The B. Braun Indonesia Charity Run 2024, themed "Run for Wellness, Run for a Cause," was held at Taman Mini Indonesia Indah (TMII) on November 17, 2024. Leading up to the event, from August to October, B. Braun Indonesia employees ran a combined 22,500 KM, raising IDR 100,000,000 for environmental conservation. These funds will support sustainable environmental initiatives across Indonesia. Company's Commitment to Renewable Energy and its Transition to Cleaner Energy Sources



B. Braun Indonesia demonstrated its
commitment to environmental responsibility
by partnering with Wastehub to plant
mangroves in Kawasan Ekowisata Mangrove,
Pantai Indah Kapuk, North Jakarta, on
November 23, 2024. This activity, along with
mangrove plantings in Jakarta and Bali, is
part of a larger initiative supported by a IDR
100 million donation to nature conservation,
aimed at restoring coastal ecosystems and
building a greener future.

Over 100 B. Braun Indonesia employees partnered with Wastehub to plant mangroves at the Kawasan Ekowisata Mangrove, Pantai Indah Kapuk, North Jakarta, on November 23, 2024. This collaborative effort demonstrates B. Braun Indonesia commitment to raising awareness about coastal ecosystem protection and accelerating nature conservation.

On December 8, 2024, B. Braun Indonesia, partnering with Wastehub, Jaringan Jurnalis Peduli Sampah (J2PS), and local fishermen, planted 500 mangrove seedlings at Wana Segara Kertih, Kedonganan, Bali. This community-focused initiative reinforces B. Braun Indonesia commitment to environmental conservation by protecting coastal ecosystems and raising awareness about the importance of mangrove preservation.

B. Braun Indonesia launched BRAUNOMOL, the first paracetamol infusion solution in Indonesia packaged in a semi-rigid container. Produced locally in Cikampek, West Java, this safe, practical, and effective solution supports Indonesia's pharmaceutical industry independence. Restoring Coastal Ecosystems and Building a Greener Future

B DRAUN

Mangroug Planting



Employees to Plant Mangroves

Planting 500 Mangrove Seedlings at Wana Segara Kertih, Kedonganan, Bali



First Paracetamol Infusion Solution in Indonesia B. Braun Indonesia inaugurated a new Technical Service facility in Cikampek, Karawang, West Java on December 11, 2024. This Technical Service facility is a strategic step by B. Braun Indonesia to support the government's program to enhance the independence of the healthcare industry in Indonesia.



B. Braun Indonesia's new Technical Service facility provides expert medical equipment maintenance, ensuring faster, more efficient, and higher-quality after-sales service, including repairs, calibrations, and spare parts. The facility also offers training programs for healthcare professionals on the safe and efficient operation and maintenance of B. Braun equipment.



B. Braun Indonesia has been awarded
a blue rating in the 2023-2024 Regional
Environmental Performance Rating
Program (PROPERDA) by the West Java
Provincial Environmental Authority.
This recognition is for the company's
environmental management performance
at the regional level, specifically at its
production facility in Cikampek, Karawang.

BRAUN BRAUNN BRAUNN BRAUNN BRAUNN BRAUN BRAUN BRAUN BRAUN BRAUN BRAUN



CEO Daewoong Pharmaceutical, Shawn Park, gave a speech at the inauguration of the Daewoong Biologics Indonesia (DBI) stem cell factory, Thursday (12/9), located in the Jababeka Industrial Area, Cikarang.

CEO Daewoong Pharmaceutical, Shawn Park (fourth from right), Deputy Minister of Health Dante Saksono Harbuwono (center), Head of BPOM Taruna Ikrar (third from right) inaugurated the stem cell factory owned by Daewoong Biologics Indonesia (DBI), a local subsidiary of Daewoong Pharmaceutical, Thursday (12/09), located in the Jababeka Industrial Area, Cikarang.



Cikaran

Biologics Indon

Health and Beauty Innova

IPMG's Vision and Focus in 2025 | CHAPTER 03 97

Head of Business Unit Daewoong Biologics Indonesia, Baik In-Hyun (center), Head of Halal Product Assurance Organizing Agency (BPJPH), Haikal Hassan (right), observed Daewoong Biologics Indonesia's GMP-certified stem cell manufacturing facility, in Cikarang, Bekasi Regency, West Java, Indonesia.



Head of Business Unit Daewoong Biologics Indonesia, Baik In-Hyun (sixth from right), Head of Halal Product Assurance Organizing Agency (BPJPH), Haikal Hassan (sixth from left), convened for a group photo during BPJPH's official visit.



Head of Business Unit Daewoong Biologics Indonesia, Baik In-Hyun (second from left), Director General of Pharmaceuticals and Medical Devices of the Indonesian Ministry of Health, Lucia Rizka Andalusia (left), Rector of the Bandung Institute of Technology, Reini Wirahadikusumah (second from right), Dean of the ITB School of Pharmacy, I Ketut Adnyana (right), inaugurated the Daewoong Drug Delivery System Laboratory, located at ITB, Bandung.

Drug Delivery System Research Institute Institut Teknologi Bandung - Derevening Foundation (DDS 81 TTB - DF) For Indi Mala Texas Institut Teknologi Bandung Particip Statem Track

IING CEREI

Daewoong DDS Lab ITB

The Director General of Pharmaceuticals and Medical Devices at the Indonesian Ministry of Health, Lucia Rizka Andalusia (third from left), observed the state-of-the-art facilities of the Daewoong Drug Delivery System Laboratory on Thursday (10/3), located at ITB in Bandung, West Java, Indonesia.



Head of the Employee Performance Team of the Ministry of Health of the Republic of Indonesia, Anik Sri Handayani, conveyed questions related to career development programs at Daewoong, during the Ministry of Health's working visit to the Daewoong facility in Osong, South Korea.



Servant Competency Development at the Indonesian Ministry of Health, Dwi Meilani (seventh from left), along with her delegation and Daewoong's management, convened for a group photo with Indonesian employees working at Daewoong.



Acting Head of BPOM, L. Rizka Andalusia (second from the right), along with her delegation, visited Daewoong Pharmaceutical's Research Laboratory in South Korea to bolster collaboration.



CEO Daewoong Pharmaceutical, Shawn Park (left) and Acting Head of BPOM, L. Rizka Andalusia (right), posed for a commemorative photo during BPOM's official visit to Daewoong Pharmaceutical's Research Laboratory in South Korea.



GSK

GSK Indonesia and GSK Global Health had the privilege of meeting with the Indonesia Minister of Health, Mr. Budi Gunadi Sadikin, and his team to discuss our shared vision for a healthier future. With over 50 years in the Indonesian market, GSK is dedicated to accelerating the introduction of innovative vaccines and medicines to meet the growing demand for preventative healthcare in Indonesia. Our discussions centered around MoU between GSK Indonesia and MoH focusing on strategies to prevent diseases and improve healthcare outcomes in Indonesia.



Partnership with MoH to address Leprosy Outbreak in Indonesia. Health authorities in Indonesia have officially declared an outbreak of leprosy, a disease that has long troubled the eastern regions of the country. This area has historically been more vulnerable to such outbreaks due to limited healthcare coverage and the highly contagious nature of leprosy. In response to this pressing health crisis, GSK Indonesia, in collaboration with the Ministry of Health, is working diligently to expedite both the special access scheme and the importation processes from GSK Regional to ensure that there is a swift and sufficient supply of leprosy medicine, a crucial medication for treating leprosy, readily available across Indonesia. This coordinated effort is vital in providing much-needed relief and support to thousands of leprosy patients during this critical time, aiming to contain the outbreak and mitigate its impact on affected communities.

Partnership with MoH to address Leprosy Outbreak in Indonesia IPMG's Vision and Focus in 2025 | CHAPTER 03

GSK - Wetland project, GSK is an investor in Climate Asset Management's Nature Based Carbon Fund, which aims to invest at a landscape scale in grassland, agriculture, forestry, wetlands and coastal carbon projects in developing economies, to provide long-lasting, verified, positive impact at scale for the climate, biodiversity and local communities. In 2024, we invested in a peat and mangrove protection and restoration project in Indonesia. Rewetting, reforestation, monitoring, and fire prevention measures will enable emission reductions and longterm carbon storage, as well as biodiversity protection. The project includes specific interventions such as training, supporting sustainable economic activities, and a Healthy Village Program, which involves initiatives such as providing capacity building to the community healthcare workers and health education for the local communities concerning sanitation, nutrition and newborn care.

Indonesia Vaccine Forum "Protecting Our Future Together" : Pioneering the first public forum to commemorate WIW 2024. Ministry of Health and four Medical Associations (GPs, Pediatrician, Internist, and midwives) together with GSK Indonesia proudly organized the first Indonesia Vaccine Forum to bring together media and mom community with experts to help improve public understanding of life course vaccination and symbolizes the collective efforts made by various stakeholders ranging from governments, medical associations to the private sector, to save many lives from diseases that can be prevented by vaccination. Climate Asset Management's Nature Based Carbon Fund



CHAPTER 03 | **IPMG's Vision and Focus in 2025**



Biodiversity Program. Fish cultivation was initiated in water canals within the factory area. This cultivation started with an initial stock of 30 Climbing Perch fish. This activity, facilitated by the GA, Legal, and OSHE Sections, aimed to prove that the recycled water is of high quality, and good enough to support aquatic life. The type of fish to be cultivated is one that is already in short supply in those areas.



Water Conservation. On January 24, 2024, a tree planting program was held as part of a water conservation initiative. In the catchment area at Mount Arjuna Welirang (1300 meters above sea level), 1,000 trees were planted to improve water retention in the area. The planted trees will be cared for by the local community, who will also benefit from the eventual harvest. The program was facilitated by the Environmental Service Agency from DLH Pasuruan, East Java, with active participation from the OSHE and GA teams from the factory. In addition to this initiative outside the factory, similar tree planting programs were also conducted on the factory area. Starting on 24 January 2024, 20 trees were planted, followed by 50 trees on 25 March 2024, and 60 more trees on 27 May 2024. These activities are coordinated by PT. Meiji Indonesia and supported by all section heads from the factory. This program is one of the company's efforts and commitment to environmental sustainability.

Tree Planting for Water Conservation: A Joint Effort Toward Sustainability Healthcare Services. PT Meiji Indonesia held free medical services and health checks in Latek Sub-District, Friday, February 21, 2025. This activity collaborates with the Puskesmas Raci in its implementation.





The Value of "People Care" in Menarini's Heart. "People care" is a commitment embedded in every action of the company. By providing access to decent education for children, Menarini is not only helping to build schools, but also planting seeds of hope for their future. The assistance in building the school at PAUD-KB Pelangi Hidayah is not just a construction project. It is a long-term investment in the development and provision of quality Indonesian human resources. With adequate learning facilities, children will have a better opportunity to develop their potential, both academically and socially.



CHAPTER 03 | IPMG's Vision and Focus in 2025

Blood Drive. Part of demonstrating "People Care" in Menarini's Heart, Menarini Indonesia held a blood donation event. It is regularly carried out quarterly as a form of concern for others and to encourage employees to reflect the company's value, namely "People Care". This blood donation activity is PT Menarini Indria Laboratories' commitment to support Indonesian Red Cross Society's efforts to meet blood needs in Indonesia. Apart from that, this activity is also means for employees to foster a sense of concern for others and is in line with the "People Care" value adopted by the company.

In partnership with Division of Pediatric Hematology Oncology, Menarini Indonesia held a workshop about chemotherapy protocols for pediatric solid cancer.

Menarini Indonesia and Indonesian Cancer Foundation Partner to Support Cancer Patients

Cancer Chemotherapy

Workshop on Pediatric Solid

In partnership with Indonesian Cancer Foundation, Menarini Indonesia eases the burden of cancer patients through its patient support program. The program provides comprehensive support that includes improving access to treatment, patient counselling and information.





105

Menarini Indonesia conducted a Myasthenia Gravis disease awareness campaign in partnership with the Myasthenia Gravis Foundation, bringing in experts to educate the audience about the condition.

> Menarini Indonesia Partners with MG Foundation to Educate Public on Myasthenia Gravis

BALANCE NUTRITION

FOR MG SURVIVOR

Jakarta, 29 Juni 2024

iravis Awareness Montr

The installation of 75kw solar panels at PT Menarini Indria Laboratories not only reduces dependence on fossil fuels, but also provides long-term benefits such as electricity cost savings and increased energy security.

Water treatment in the factory is an important process to ensure that the water used for various purposes, including watering plants, is safe and clean.



Merck

On March 7, 2024, Merck hosted a media conference to announce the re-launch of www.MauPunyaAnak.id platform. This collaborative effort between Merck and PEFITRI (Indonesian In-Vitro Fertilization Association) aims to support couples in their journey towards parenthood. The platform provides access to crucial information and medical support, addressing the challenges of infertility and helping couples realize their dream of becoming parents.



PT Merck Tbk in collaboration with Siloam Hospitals Lippo Village conducted a media event (May 28, 2024) commemorating World MS Day to raise MS awareness and reduce the risk of MS underdiagnosis and delayed treatment. Presented speakers of dr. Rocksy, Neurologist of Siloam Hospitals Lippo Village and Jessy, MS patient and social media influencer, we underscored the importance of MS early and the right diagnosis, as well as our commitment to expanding access to innovative and high-quality MS treatments.



The Indonesia Women in Leadership (I WIL) Network of PT Merck Tbk, in collaboration with the Plan Indonesia Foundation, launched the Decent Sanitation and Menstrual Hygiene at School (DEAREST) program to improve sanitation facilities and menstrual hygiene education in schools in Sukabumi, West Java, Indonesia. Funded by the Merck Family Foundation, the initiative has been implemented in five schools, enhancing the hygiene practices of both students and teachers. The program includes the renovation of 74 toilet stalls across 18 blocks. It highlights the program's impact on the health and well-being of children in Sukabumi, West Java, aiming to foster equality and significant improvements in educational environments, especially for girls.



On June 12, 2024, twenty employees of PT Merck Tbk, members of I WIL, visited SMPN 1 Sukaraja to engage in educational volunteering activities focused on sexual and reproductive health rights and menstrual hygiene management. They also conducted a Career Talk session about various job roles in the healthcare and life sciences industry for over 250 students from various middle and high schools.

PT Merck Tbk celebrated its 54th anniversary by conducting the Merck Life Festival throughout October 2024, focused on the theme of "Impactful Living," which emphasizes positive impacts through daily actions. The festival featured a pre-event phase with social media content under #SiKenali, a livestreamed Curious Talk on healthcare topics, and #ImpactfulLiving Day, where employees and external volunteers engaged in science activities for children with disabilities. Overall, the festival reached 1.5 million people through social media and attracted 2,500 live viewers during the event.

As part of the celebration of Merck's 54th anniversary in Indonesia and the 50th anniversary of the Jakarta (Pasar Rebo) Site, PT Merck Tbk inaugurated the installation of photovoltaic (PV) solar panels on the roof of the Merck Indonesia factory in Pasar Rebo, East Jakarta (22 Oct 2024). This step represents Merck's commitment to promoting the company's transition to renewable energy. This initiative aligns with the sustainability targets of the Merck Group, including the goal of reducing greenhouse gas (GHG) emissions. It is hoped that these solar panels will contribute 12% of the factory's total annual energy needs and reduce GHG emissions by 465.3 tons of CO2, thereby decreasing dependence on conventional energy sources. Through the inauguration of this solar panel installation, Merck aims to ensure that its operations are environmentally friendly and sustainable.

Merck Indonesia Inaugurates Solar Panel Installation to Mark 54th Anniversary and Advance Sustainability Goals

Peresmian Instalasi

rya PT Merck Tb





On November 5, 2024, PT Merck Tbk in collaboration with CHAMPS UI held a Thyroid Policy Dialogue to build synergy and collaborations among stakeholders, experts, medical associations, policy makers and community organizations in development of thyroid screening policy especially in highrisk populations, raise awareness about the important of regular screenings for thyroid disorders and discuss financing mechanisms that can support ongoing program of thyroid screening. The dialogue followed by a press conference to launch the White Paper "Closing The Gap: Prioritizing Thyroid Disease in Asia Pacific" in Indonesia. Alexander de Muralt, Senior Vice President, Merck Healthcare APAC handed over the White Paper to Prof. dr. Dante Saksono Harbuwono, Sp.PD-KEMD., Ph.D., Vice Minister of Health, ID Ministry of Health.





To commemorate National Heroes Day and in anticipation of National Health Day, MSD Indonesia organized the #NgobrolinHPV RUN, aiming to inspire the public to become health heroes by increasing understanding and awareness of the dangers of Human Papilloma Virus (HPV) infection. Today's #NgobrolinHPV RUN, which brought together various sectors of society, aligns with the spirit of "Moving Together, Healthy Together," the theme of National Health Day 2024.



IPMG's Vision and Focus in 2025 | CHAPTER 03

The "Tenang untuk Menang" health education campaign is a collaborative initiative aimed at increasing public understanding of the importance of HPV immunization to prevent the spread of cervical cancer in Indonesia, as well as its impact on improving the health quality of future generations. This campaign, themed "Indonesian Women Free from the Dangers of Cervical Cancer," was launched in Jakarta on August 13, 2024, and was attended by key stakeholders from various government ministries, the health sector, and community leaders-including Minhajul Ngabidin (Ministry of Education, Culture, Research, and Technology), George Stylianou



(Managing Director, MSD Indonesia), Emanuel Melkiades Laka Lena (Vice Chairman, Commission IX, DPR RI), Dr. Yudhi Pramono (Acting Director General of Disease Prevention and Control, Ministry of Health), Dr. Prima Yosephine (Director of Immunization Management, Ministry of Health), Dr. Santi Yanti Kalangi (Head of Secondary Education Sub-Directorate, Ministry of Religious Affairs), Shadiq Akasya (President Director, Bio Farma), and Dr. TB. Chaerul Dwi Sapta (Director of Regional Government Affairs Synchronization III, Ministry of Home Affairs).

Through this campaign, MSD Indonesia, together with the Ministry of Health and Bio Farma, invites the publicespecially women and parents-to actively participate in the fight against cervical cancer by getting the HPV vaccine. The initiative is part of the national commitment to eliminate cervical cancer and improve the overall health of Indonesia's future generations

The "Close the Care Gap" Art Exhibition was organized by MSD Indonesia in collaboration with the Indonesian Cancer Foundation (YKI) on Sunday, February 4, in Tangerang, as part of the 2024 World Cancer Day commemoration attended by the Minister of Health of the Republic of Indonesia, Budi Gunadi Sadikin; Chairperson of the Indonesian Cancer Foundation, Prof. Dr. dr. Aru Wisaksono, SpPD-KHOM, FINASIM; Shahnaz Haque; Indro "Warkop"; Bambang Reguna Bukit (Bams); and representatives from MSD Indonesia.



The exhibition, titled "Close the Care Gap,"

showcased over 100 artworks by cancer survivors-including paintings, typography, photographs, and other creative works-sharing the personal journeys of cancer warriors. In addition, MSD Indonesia introduced @ NgobrolinKanker, a trusted education and information center about cancer, aiming to bridge the information gap on cancer within the community.

As a collaborative effort to support the improvement of the School Children Immunization Month (BIAS) program in Bogor Regency, Jalin Foundation, together with the Ministry of Health and the Bogor District Health Office, initiated the #ImunisasiltuBaik and #ImunisasiPasti campaigns. These campaigns focus on providing access to immunization for children aged 7–12, both in and out of school. Jalin Foundation received a grant from MSD through the Global Solutions for Healthy Communities program to support this initiative.



The campaigns have successfully increased immunization coverage in Bogor Regency, involving more than 20,000 individuals through educational sessions and outreach activities. The program also utilizes social media to combat misinformation and works across sectors to reach children outside the formal school system. This approach has resulted in a significant rise in immunization participation, demonstrating the importance of inclusive, community-based, and cross-sector collaboration for public health advancement

To raise awareness and broaden public understanding of HPV, MSD Indonesia held an event titled #NgobrolinHPV Live!: Night at the Library at Jakarta Library, Taman Ismail Marzuki, on Thursday, April 25, 2024. The event featured expert speakers, including dermatologist and venereology consultant Dr. Hanny Nilasari, Director of Immunization Management at the Ministry of Health Dr. Prima Yosephine, #NgobrolinHPV educator Maudy Ayunda, and was moderated by Iyas Lawrence.

#NgobrolinHPV Live! not only presented a talk show about HPV and the dangers of



HPV infection, but also included informative discussions and important health messages, emphasizing the need for open information sharing and awareness about HPV-related diseases. The event aimed to break the stigma surrounding HPV, encourage preventive measures such as vaccination and screening, and empower the community to prioritize their health through credible information

Refor

Penanamo



Mitsubishi Tanabe Pharma

One tree a million benefits. PT Mitsubishi Tanabe Pharma Indonesia and ALKIM 7 are collaborating in planting tree seedlings as a form of attention to the environment.

> Tree Planting Collaboration by Mitsubishi Tanabe Pharma and ALKIM 7 to Support the Environment

Zero waste to landfill. PT Mitsubishi Tanabe Pharma Indonesia and the local government collaborate in independent waste management with the result that no waste is dumped in landfills (zero waste).

> Mitsubishi Tanabe Pharma Indonesia and Local Government Achieve Sustainable Waste Management



The initiative "takeaction" aims to empower employees to champion causes about which they are passionate, striving to make a positive difference in people's lives and the environment through volunteer efforts. In 2024, takeaction collected more than 246 kg of beach plastic waste, which was utilized in creating prosthetic legs to support the disability community.

The Affordability Project, in collaboration with the Ministry of Health and local authorities, aims to provide diabetes management in rural and remote areas, removing barriers to access care. In 2024, 191 healthcare professionals and 920 cadres were trained to educate and screen across 46 Puskesmas in 4 districts of West Java, screening more than 278,000 people for NCD risks.

Changing Diabetes® in Children (CDiC) Indonesia is an initiative aimed at providing diabetes care to children and youth with type 1 diabetes. With the goal of preventing fatalities due to diabetes among children, we have established four key components of comprehensive care: 1) Providing patient education, 2) enhancing the capacity of healthcare professionals, 3) bringing care closer to those in need, and 4) ensuring access to insulin and related supplies. This initiative is pivotal in addressing the needs of young individuals affected by diabetes. TAKEACTION" Initiative

Combines Environmental Cleanup with Disability Support





IPMG's Vision and Focus in 2025 | CHAPTER 03

113

Novo Nordisk Indonesia and Bio Farma have signed a memorandum of understanding (MoU) to collaborate on producing diabetes medicines in Indonesia. By combining expertise, both entities aim to support the Indonesian government in providing essential diabetes medications, aligning with the government's healthcare resilience agenda.

On World Diabetes Day, we organized a global diabetes walk to mark its 20th anniversary, aiming to enhance public awareness and encourage participation. Alongside this event, we hosted a media and influencer gathering, leveraging their influence to amplify awareness about diabetes. Novo Nordisk and Bio Farma Partner to Advance Diabetes Medicine Production in Indonesia

artnership in Insulin Manufacturing Process Bio Farma and Novo Nordisk



- ORGANON

In collaboration with the Blood Transfusion Service Unit of the Indonesian Red Cross (UPTD PMI) Pasuruan Regency. February 29, 2024 = 31 donors; May 21, 2024 = 33 donors; September 11, 2024 = 21 donors.



114 CHAPTER 03 | **IPMG's Vision and Focus in 2025**

- March 5, 2024 41 participants from:
- Village midwives of Karangjati, Pandaan, Pasuruan
- Health cadres from 8 hamlets in Karangjati Village
- Members of the Family Welfare Movement (PKK) in the Karangjati Village area, Pandaan, Pasuruan



In collaboration with the Karangjati Village Midwife and Jati Sehat Health Cadres, routine monthly activities are carried out as follows:

- Stunting Posyandu/POSTING (Integrated Health Post for Stunting)
- Classes for Pregnant Women & Mothers
 of Toddlers
- Family Posyandu (Integrated Family Health Post)



Stunting Alleviation & Support for Pregnant Women

Support for the Adiwiyata Green School Program in the Form of Renovation of SDN Karangjati 1, Kelitengah, Pandaan. October 15, 2024



IPMG's Vision and Focus in 2025 | CHAPTER 03

Disease Awareness Campaign: Socialization on Prevention, Eradication, Abuse, and Illicit Trafficking of Narcotics (P4GN). November 14, 2024. Number of participants: 52 people (representatives from village officials, hamlets, health cadres, and residents).

Dengue Fever (DHF) Alleviation through Jumantik (Larvae Monitoring Officers) Activities

> Combating Dengue Fever Through Jumantik (Larvae Monitoring Officer) Activities

Empowering Communities Against Drugs: P4GN Awareness Session Reaches 52 Participants





116 CHAPTER 03 | IPMG's Vision and Focus in 2025

Otsuka

Otsuka Group in Indonesia achieved "Exemplar Award" from Ending Workplace Tuberculosis (EWTB) by The World Economic Forum for its efforts in tackling Tuberculosis, announced in conjunction with the momentum of celebrating World Tuberculosis Day 2024.

Otsuka Group Honored with Exemplar Award by EWTB on World Tuberculosis Day 2024

Otsuka Group in Indonesia received a Certificate of Appreciation in recognition and appreciation for initiating the FREE TBC at Workplaces Program, by Ministry of Health, at the Peak Event of World Tuberculosis Day 2024 with the theme "GIAT: Indonesia's Movement to End Tuberculosis".

> GIAT: Indonesia's Movement to End Tuberculosis

PT Otsuka Indonesia received award of forest and land rehabilitation CSR in the forest Malang by East Java Provincial forestry Service on conservation activities to save the springs on the slopes of Mount Arjuno, apart from being a contribution to saving the environment, also serve as education for the younger generation to be more aware of the environment.



Otsuka Indonesia Honored for Conservation Efforts to Protect Springs on Mount Arjuno



Pfizer Indonesia in collaboration with Indonesian Neurologist Association (Perdosni) conducted a series of educational programs for both HCPs and the public to commemorate Migraine Awareness Month.

Pfizer Indonesia in collaboration with Rise Against Hunger, an international hunger relief organization, held a social activity on 11 and 13 November 2024 to support the fight against malnutrition in the country. More than 200 Pfizer Indonesia employees took part in preparing over 75,000 nutritional meal packages.



Pfizer Indonesia and Rise against Hunger Collaborate to Pack 75,000 Meal Packs


To help patients in obtaining breast cancer health consultation services, Pfizer Indonesia signed a cooperation agreement with Siloam MRCCC Semanggi Hospital (MRCCC).



To help patients in obtaining breast cancer health consultation services, Pfizer Indonesia signed a cooperation agreement with Mandaya Royal Hospital Puri (MRHP).

Pfizer Indonesia actively works to enhance the capacity of healthcare professionals in patient care through various initiatives. One of our initiatives is providing training for healthcare workers on migraine at Mitra Keluarga Hospital.

Pfizer Indonesia partnered with the Indonesian Public Health Experts Association (IAKMI) in holding a public talk show titled "Bersama Cegah Pneumonia, Menuju Indonesia Emas 2045", inviting stakeholders from the government, health experts, communities, and media, as part of the commemoration of World Pneumonia Day which falls every November 12.



Training for Healthcare Workers on Migraine



10

119

2 Pfizer

Pfizer works together with Aspire Institute in conducting Aspire Leaders Program for first generation college students in Indonesia by actively promoting the program.

Pfizer Indonesia Supports PERDOKI's Efforts in Promoting Workers' Health and Safety at Indonesian Occupational Medicine Updates (IOMU) 2024. Pfizer Indonesia supports Indonesian Association of Occupational Medicine Physicians or PERDOKI's efforts in promoting workers' ealth and safety at the 16th Indonesian Occupational Medicine Updates (IOMU) 2024.

Pfizer Indonesia and Yayasan Haji Muslimat NU Collaborate in a Health Awareness Talkshow on Pneumonia. Yayasan Haji Muslimat NU held a talk show titled "Health Awareness: Preventing Pneumonia Risk for Hajj and Umrah Pilgrims" in Malang and Surabaya to emphasize the importance of health protocols, including pneumonia vaccination, to enhance the safety of Hajj and Umrah pilgrimage journeys. with Aspire Program

Aspire Leaders

Program

BATCH 2 Unlock Your Potential

> PROTECTION AGAINST PNEUMONIA

Pfizer Indonesia Supports PERDOKI in Advancing Workplace Health and Safety at IOMU 2024

Pfizer and Yayasan Haji Muslimat NU Raise Pneumonia Awareness for Safer Pilgrimage Roche

Continuing our efforts in shaping the healthcare system, 2024 marked significant progress in cancer patient navigation and specialized nursing education. A total of 21 Cancer Patient Navigators successfully graduated from their program, further strengthening patient support and care coordination. Additionally, 48 nurses enrolled in a master's program in UGM that incorporates the Cancer Patient Navigator (CPN) curriculum, enhancing expertise in oncology care. Additionally, two training centers were established to support the implementation of Oncology Nursing Society (ONS) and CPN guidelines within multidisciplinary team (MDT) regulations and the national cancer network framework.



It is the company's employee-driven fundraising event that encourages employees in using their talent and creativity to raise funds and helping those in need. Through various fundraising activities, Roche Indonesia employees managed to donate IDR 181,053,063 to Yayasan Kasih Anak Kanker Indonesia in 2024.



SERVIER,*

Local celebration of Servier Group 70th Anniversary & the announcement of the GPTW certified for 3 consecutive years.

RenoFUN Week - supporting the renovation of LP4Y's Training Development Center in Cilincing area by involving employees and the youth of LP4Y

The Kick-off of AccelerAction Program Batch 2 for LP4Y Jakarta









It is a collaborative initiative to strengthen dengue prevention efforts in Indonesia. Since its launch in 2023, the program has engaged over 15,000 participants across Jakarta, Surabaya, Bandung, and Medan, working alongside the Ministry of Health, local governments, healthcare professionals, and communities. As a long-term partner, Takeda remains committed to supporting the goal of Zero Dengue Deaths by 2030—through innovative prevention and beyond.

Dengue remains a serious public health threat, particularly affecting Indonesia's working-age population. Launched in November 2024, SIAP (Sinergi Aksi Perusahaan) Lawan Dengue is a collaborative movement by Takeda, KADIN, the Ministry of Health, the Ministry of Manpower, Bio Farma, and PERDOKI to protect employees through education, 3M Plus movement, and vaccination. With 55 pioneer companies leading the way, this initiative continues to drive collective action, ensuring a healthier and more resilient workforce.

On September 15, 2023, in conjunction with Lymphoma Awareness Month, PT Takeda Indonesia supported Cancer Information and Support Center (CISC) to host a powerful media event focused on early detection and optimal care for lymphoma patients. Engaging discussions among patients, experts, and healthcare leaders reaffirmed our commitment to the highest care standards. The event generated robust media coverage and heightened public awareness. Through multi-sector collaboration, we continue to enhance the quality of life for lymphoma patients. Collaborative Initiative to Strengthen Dengue Prevention Efforts





PT Takeda Innovative Medicines launched the inaugural Indonesia Dengue Summit (IDS) on June 23, 2024, aligning with ASEAN Dengue Day's spirit of action. This event brought together key health experts, government leaders, and communities to address dengue's growing threat. The summit emphasized the importance of vaccination, collaboration, and proactive engagement to protect families and communities from the impact of dengue, with Takeda committed as a trusted partner in the fight.

PT Takeda Innovative Medicines, in collaboration with PKJS-UI, commemorated International Women's Day 2024 through a public discussion on Building Women's Leadership in the Healthcare Sector. Featuring inspiring leaders, including Michelle Erwee, Takeda's Global Head of Access, the event highlighted Takeda's commitment to gender equality. With strong engagement and support from the MoH and the Ministry of Women's Empowerment, the discussion reinforced the importance of women's leadership in healthcare.

At the 2024 International Arbovirus Summit in Bali, Takeda joined global leaders in addressing the growing threat of arbovirus diseases. Dr. Nikki Kitikiti, Takeda's Vaccine Policy expert, contributed insights on advancing vaccine solutions. Collaborating with Indonesia and Brazil's Ministries of Health, we explored innovative strategies for virus control, reflecting our shared commitment to tackling public health challenges like dengue.



International Women's Day 2024 Commemoration



124 CHAPTER 03 | **IPMG's Vision and Focus in 2025**

On December 7, 2024, Takeda Indonesia took the opportunity to highlight the importance of speaking up on IBD journey through IBD Talk Show in collaboration with Indonesian Gastroenterology Indonesia. This activity was attended by IBD Patients from nationwide involving some IBD patient groups (36 patients from Jabodetabek & more than 100 IBD patients joined the event through YGI's IG account). The high level of interaction from the audience to the speakers indicate success in creating active and informative discussion, reflected on the enthusiasm of the audience in the Q & A session.



Inflammatory Bowel Disease (IBD) Patient Gathering on "UC & CD Awareness Week"



Members' Awards and Recognitions



AstraZeneca

- The prestigious 'Change the World'. (Issued by Fortune Indonesia)
- Commitment to Sustainability. (Issued by Eurochamp)
- Best Company to Work For in Asia. (Issued by HR Asia Awards)

AstraZeneca 🔗

Best Place to Work. *(Issued by the Great Place to Work Institute)* AstraZeneca's commitment to creating a positive and supportive work environment for all employees.

		Bayer
BAYER E R	•	Commitment award. The Occupational Safety and Health (K3) West Java Province. <i>(Awarded by: Governor West Java)</i>
	٠	CSR Award. Best of Corporate Social Responsibility in Depok. (Awarded by: Mayor of Depok)
	•	Gold. The Occupational Safety and Health Steering Committee (P2K3) Award. <i>(Awarded by the Governor of West Java)</i>
	•	Zero Accident Award. Zero Accident Award for achievements in implementing Occupational Safety and Health (K3) programs. <i>(Awarded by</i>


implementing Occupational Safety and Health (K3) programs. (Awarded by the Governor of West Java)

B Braun

B BRAUN

- Great Place to Work Certification. (Issued by: Great Place to Work Institute)
- PROPERDA Blue Rank. Given to the company's performance in environmental management. (Issued by Karawang Environment Authority)
- PROPERDA Blue Rank. Given the company's performance in environmental management. (Issued by West Java Environment Authority)







- PR Program of the Year 2024 for Internal PR Fertility Benefit Program. (Issued by Mix Marketing & Communication)
- CEO Excellence Awards 2024. Innovating Healthcare Solutions While Advancing Renewable Energy Initiatives. *(Issued by Warta Ekonomi.co.id)*

Merck Sharp & Dohme

Mitsubishi Tanabe Pharma



• Excellence in Work-Life Harmony. (Issued by HR Excellence Award)

Mitsubishi Tanabe Pharma

- PROPER Blue Rank. Public Disclosure Program for Environmental Compliance. *(Issued by the Ministry of Environment and Forestry)*
- First Rank: Best Foreign Investment Business in 2023. (Issued at the Bandung City Investment and One-Stop Integrated Service Agency (DPMPTSP) at Bandung Investment Summit 2024)

Novartis Indonesia

UNOVARTIS

- Top Employer Award. (Issued by The Top Employers Institute)
- Innovation Award for in-market brands by APMA (Asia Pacific Middle East & Africa) Region.

Novo Nordisk Indonesia



- Best Company in Diabetes Prevention & Control. Recognized by the Ministry of Health.
- Indonesia's Best Place to Work in 2024. Recognized by the Best Places to Work.



- Certificate of Appreciation in recognition and appreciation for initiating FREE TBC at Workplaces Program, by Ministry of Health
- Ending Workplace TBC (EWTB) Exemplar Award. (Issued by The World Economic Forum)
- Award of forest and land rehabilitation CSR in the Malang. (Issued by East Java Provincial Forestry Office)
- Award for environmental protection and management in Malang Regency. *(Issued by Malang Regency Office)*

Pfizer Indonesia

Otsuka Indonesia

29



Gold Award for Excellence in Social Media Marketing. Marketing Excellence Awards 2024 Indonesia.

Servier Indonesia

Takeda Indonesia

SERVIER

Great Place to Work 2024. (Issued by The Great Place to Work Institute)



- Great Place to Work Certification for Takeda's strong commitment to create a positive and inclusive work environment that empowers every employee to grow personally and professionally. *(Issued by The Great Place to Work Institute)*
- PR Indonesia Awards 2024 for category Program PR: Corporate PR (Bronze).





Ani Rahardjo

Executive Director



Atika Gadis Parengkuan

Public Affairs and Communications Lead



Jony D. Radja

Administration and Membership Services Manager

Nathanael Jusaac Lie

Project Officer

International Pharmaceutical Manufacturers Group (IPMG)

Pondok Indah Office Tower 1. Third Floor. Suite 308 Jalan Sultan Iskandar Muda Kavling V-TA Jakarta 12310 Indonesia

Phone: +62 21 7697531Fax: +62 21 7697532Email: ipmg@ipmg-online.comWebsite<th: www.ipmg-online.com</th>LinkedIn:IPMG Int'l Pharma Manufacturers Group

